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ABSTRACT
Assembly of functional nanocomponents offers promising applications in drug delivery to solid
tumors and bottom-up synthesis and integration of nanodevices. This thesis presents a novel multistage
nanoparticle delivery system consisting of an assembly of nanoparticles that can change its size to
facilitate transport into solid tumors. Current FDA-approved nanotherapeutics, which function based on
the enhanced permeation and retention (EPR) effect, suffer from poor penetration into the extravascular
regions of the tumor due to the dense collagen matrix, resulting in heterogeneous therapeutic effects and
likely contributing to tumor regression and development of resistance. We propose a multistage
nanoparticle system that "shrinks" when it extravasates into the tumor and is exposed to the tumor
microenvironment, allowing enhanced penetration into the tumor parenchyma. This "shrinkage" is
preferentially triggered in the tumor through cleavage by MMPs, proteases highly expressed in the tumor
microenvironment. A multistage nanoparticle system allows us to engineer the size and surface properties
of each stage independently for preferential transvascular transport into tumors and high diffusion in the
tumor's interstitial space. To our knowledge, this work is the first demonstration of a size-changing
nanoparticle delivery system in vivo. Multistage nanoparticle delivery systems provide a promising
approach to improving the delivery of anticancer agents into solid tumors and as a result the enhancement
of the drug's therapeutic efficacy.
Another area that necessitates the controlled assembly of nanocomponents is in the integration of
nanodevices and nanocircuitry. We have developed a method of combining the synthesis and assembly of
semiconducting nanowires in a single step using electrically controlled catalytic nanowire growth. Our
results demonstrate electric field-modulated nanowire growth that can be used as a simple and
inexpensive method for fabricating and integrating nanoscale devices.
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Title: Lester Wolfe Professor in Chemistry
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Chapter 1
Introduction
1.1 Tumor Biology
A tumor is an abnormal mass of tissue that arises from preexisting cells through uncontrolled cell
division. Tumors can be either benign (localized, noninvasive) or malignant (invasive, metastatic,
cancerous). Tumor formation is a complex multi-step process driven by a sequence of randomly occurring
mutations and epigenetic alterations, the latter being promoter methylation of DNA, that affect the genes
controlling cell proliferation, survival, and other traits associated with the malignant cell phenotype.
These alterations require activation of oncogenes with dominant gain of function and inactivation of
tumor suppressor genes with recessive loss of function. Some of these changes arise as a result of
exogenous mutagens such as chemical agents, radiation, and viruses or by random error in the DNA
replication process. The rate of expansion of mutant cell clones may also be governed by nonmutagenic
tumor-promoting stimuli, including chronic mitogenic stimulation and inflammation. Multi-step tumor
progression can be depicted as a form of Darwinian evolution occurring within tissues, in which a
sequence of genetic alterations, each conferring one or another type of growth advantage, leads to the
progressive conversion of normal human cells to cancer cells. A Darwinian model of cancer progression
is attractive but oversimplistic and must be modified to account for critical changes in tumorigenesis that
diverges from Darwinian evolution - such as epigenetic alterations, cancer stem cells, and clonal
diversification due to high mutation rates. Weinberg and others (1, 2) have identified seven essential
changes (hallmarks) in cell physiology, acquired during multistep tumorigenesis, that together define all
types of malignant growth, each of which represents the neoplastic cell surmounting an anticancer
defense mechanism built into cells and tissues.
1. Self-Sufficiency in Growth Signals. Mitogenic growth signals (GS) are required for normal cells to
move into an active proliferative state, thus regulating cell division to generate the proper number of
cells within a tissue or organ. These signals are transmitted into the cell by transmembrane receptors
that bind distinctive classes of signaling molecules: diffusible growth factors, extracellular matrix
components, and cell-to-cell adhesion/interaction molecules. Tumor cells generate many of their own
signals, reducing their dependence on stimulation from their normal tissue microenvironment. This
acquired GS autonomy can be achieved by five common mechanisms: alteration of extracellular
growth signals (e.g., autocrine signaling loops, GS from recruited stromal cells); alteration of
transcellular transducers of those signals (e.g., overexpression of cell surface receptors (e.g., EGF-
R/erbB and Her2/neu (3)); structural alteration of receptors ; type switch of extracellular receptors
(e.g., switch to integrins that transmit progrowth signals); or alterations of intracellular circuits that
translate those signals into action (e.g., mutation in the SOS-Ras-Raf-MAPK cascade).
2. Insensitivity to Antigrowth Signals. Normal tissues produce multiple anti-proliferative signals to
maintain cellular quiescence and tissue homeostasis. Developing cancer cells must evade these
antiproliferative signals if they are to thrive. Growth inhibitory signals are usually associated with the
cell cycle, in particular the G phase where the cells monitor their external environment and decide
whether to proliferate, be quiescent (Go), or enter into a post-mitotic state. Many and perhaps all of
these antiproliferative signals are funneled through the retinoblastoma protein (pRb) (4) and its two
relatives, p107 and p130. The inhibitory signals (e.g., the soluble signaling molecule TGF-0) result in
a hypophosphorylated state of pRb which blocks proliferation by sequestering E2F transcription
factor that controls the expression of a large number of genes responsible for progression from G
into S phase. When the pRb signaling circuit is disrupted (e.g., through alterations in transcellular
transducers (TGF-3R), alterations in cytoplasmic signaling proteins (e.g., p1 5INK4B, Smads, pRB), or
the E7 oncoprotein of human papillomavirus which can sequesters pRB) and E2F is liberated, the
cells become insensitive to antigrowth factors, allowing the cell to proceed with the cell divison cycle.
In addition to avoidance of antigrowth signals, tumors also use diverse mechanisms to avoid cells
from entering into a post-mitotic, differentiated state (e.g., overexpression of the c-Myc oncoprotein
and activation of the APC/3-catenin pathway).
3. Evading Apoptosis. In order for a tumor cell population to flourish, it must not only grow rapidly but
also avoid cell death. A major source of cell death is apoptosis, programmed cell death. The cell
senses the intracellular and extracellular environment for conditions of normality or abnormality that
decide cellular fate. Intracellular sensors monitor the cell's well-being and activate apoptosis in
response to abnormalities such as anoxia, hypoxia, damage to the genome, signaling imbalances in
the growth-regulating machinery, survival factor insufficiency, or loss of anchorage. Extracellular
sensors can transmit survival signals (e.g., survival factor IGF-1/IGF-2 by their receptor IGF-lR, IL-3
by its receptor IL-3R, cell-cell and cell-matrix adherence-based signals) or death signals (FAS by
FAS receptor (5), TNF-a by its receptor TNF-R1). Loss of the tumor suppressor p53 (changes in the
p53 gene or upstream regulators), which can instigate the apoptotic cascade by sensing cell
abnormalities, can make cancer cells become resistant to apoptosis (6), allowing it to survive a variety
of cell-physiologic stresses. Cancer cells have developed numerous other methods to inactivate the
apoptotic machinery such as activation of the survival signaling pathway P13-kinase-AKT/PKB (can
be activated by extracellular signals IGF-1/2 or IL-3, Ras, or loss of the tumor suppressor pTEN),
increase levels of anti-apoptotic Bcl-2, inhibition of caspases, and interference with cytochrome c
release.
4. Limitless Replicative Potential. Normal cells in culture were observed to replicate a finite number of
times, after which they enter into a nonproliferative state known as senescence (7). However, by
disabling the pRb and p53 tumor suppressor proteins in certain cells, the cells are allowed to replicate
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for additional generations until they enter into a second state known as crisis. During crisis, end-to-
end chromosome fusion (due to telomere shortening) results in karyotypic disarray and almost always
cell death (8). However, very rarely, a mutated cell emerges from crisis with acquired unlimited
replicative potential, a trait known as immortalization. These rare cancer cells can escape crisis by
telomere elongation through either upregulation of telomerase or a mechanism known as ALT
(alternative lengthening of telomeres) (9).
5. Sustained Angiogenesis. Angiogenesis is the growth of new blood vessels from pre-existing vessels.
Virtually all cells in tissue must dwell within 100 pim from capillary blood vessels to receive the
oxygen and nutrients crucial for cell function and survival. The cells in tumors initially lack the
ability to grow new blood vessels, limiting their ability for expansion. In order to progress to a larger
size, tumors must encourage angiogenesis by changing the balance of angiogenesis inducers (e.g.,
VEGF (10), FGFl/2) and countervailing inhibitors (e.g., thrombospondin-1, -interferon) (11). This
ability to induce and sustain angiogenesis seems to be acquired in a discrete step (or steps) during
tumor development termed the "angiogenic switch" (12). It has been shown that upregulation of ras,
loss of p53, and extracellular proteases that release sequestered GFs in the ECM (e.g. MMPs,
Cathepsin D) can shift the balance in favor of angiogenesis inducers. Moreover, integrins and
adhesion molecules also play critical roles in angiogenesis (13).
6. Tumor Invasion and Metastasis. Primary tumors eventually generate cells that move out, invade
nearby tissue, and journey to distant sites where they may form new colonies known as metastases.
These distant colonies of tumor cells are the cause of 90% of cancer mortality. The invasion-
metastasis cascade is a complex process involving local invasion, intravasation, transport,
extravasation, formation of micrometastases, and colonization. Many of these steps can be executed
by carcinoma cells that activate the cell-biological program called the epithelial-mesenchymal
transition (EMT) (14), which is normally used by cells early in embryogenesis and during wound
healing. This program involves changes in the attachment of cells to their microenvironment (e.g.,
CAMs of the immunoglobulin and cadherin family, integrins) and activation of extracellular proteases
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that cleave the ECM creating space for the cells to move (MMPs). Loss of E-cadherin plays the
dominant role in influencing epithelial versus mesenchymal cell phenotypes. E-cadherin forms
homodimeric (and higher-order) bridges between adjacent cells in an epithelial cell layer. Loss of E-
cadherin from the plasma membrane liberates f-catenin molecules, which may then migrate to the
nucleus and associate with Tcf/Lef transcription factors (15), thereby inducing expression of genes
orchestrating the EMT program.
7. Avoidance of Immunosurveilance. The immune system eliminates infectious agents as well as
cancer cells through humoral and cellular immunity. Humoral immune responses are likely
responsible for preventing virus-induced tumors through suppression of the infectious spread of virus.
Cellular immune responses (e.g., cytotoxic T cells) are responsible for eliminating virus-transformed
tumor cells that present antigenic viral oligopeptides through MHC class I proteins. The role that
immune cells play in suppression of tumors of nonviral origin is more poorly understood. Tumor cells
present few antigens that are clearly foreign (weakly antigenic), and thus may escape detection from
the tolerance that the immune system develops toward "self' proteins. Some tumor cells attract the
attention of immune system by expressing proteins in aberrant amounts or proteins that are normally
displayed only on cell surface in embryos or in immunologically privilege sites. Tumor cells escape
immune responses, termed cancer immunosurveilance, by immunoselection (e.g., suppression of
tumor-associated antigens and generation of weakly antigenic variants through immunoediting) or by
immunosubversion (e.g., killing immune cells using pro-apoptotic factors such as TGF-3 and FasL,
release of chemotactic factor CCL22 which attracts regulatory T cells to suppress activation of the
immune system) (1).
+1. Genomic Instability. Cancer cells acquire the seven capabilities enabling tumor development
through changes in their genome. However, mutation of specific genes is inefficient due to the
multiple DNA monitoring and repair mechanisms in somatic cells, bringing into question how cancer
can appear at such high frequency in the period of several decades. The fidelity of cell division is
ensured by cell cycle checkpoints and the "caretaker" system that provides DNA maintenance.
Defects in genes that are involved in the maintenance of genomic integrity generate substantially
increased risk of tumors. Mutant alleles of the BRCA1 and BRCA2 genes (16), responsible for DNA
homology-dependent repair, increase an individual's susceptibility to breast and ovarian cancer. In
hereditary nonpolyposis colorectal cancer (HNPCC), inherited mutations in the DNA mismatch repair
pathway lead to high risk of colon cancer. The tumor suppressor p53 ("the guardian of the genome"),
in response to DNA damage, can elicit cell cycle arrest or apoptosis. Mutation in the p53 signaling
pathway (along with proteins for DNA repair and chromosomal segregation) can lead to genome
instability (17) and generation of mutant cells with selective advantages.
1.2 Cancer Therapy
Conventional therapy for cancer can be divided into local therapy (surgery and radiation) and
systemic therapy (chemotherapy, hormonal therapy, monoclonal antibodies, and radioactive materials).
The modality used depends on the tumor grade, stage of the disease, location of the tumor, and the state of
the patient's health (performance status). The intent of a certain treatment modality may be curative,
adjuvant (additional treatment after the primary treatment), neoadjuvant (treatment prior to primary
treatment), therapeutic (has survival benefits, may be curative) or palliative (in situations where cure is
not possible, used for disease control or relieve of symptoms). Multiple modalities are frequently
combined for an additive/synergistic effect.
Surgery is quick, effective, allows recovery of tumor biopsy for pathological analysis, and the
main curative therapy for many common solid tumors if the tumor is resected in its entirety. Microscopic
invasion of surrounding normal tissue will necessitate analysis of multiple cytosections to ensure the
entire tumor is removed. Tumor cells that are not removed can result in local or distant recurrence(s).
However, removal of all the tumor cells is not possible when the tumor has become invasive and has
metastasized to other parts of the body prior to surgery, as is often the case due to diagnosis at a late-stage.
In addition, surgeons have observed that excision of certain types of primary tumors may be followed by
rapid growth of distant metastases. The growth of the metastases may be stimulated by wound healing
from the surgery (inflammatory response) and/or cell migration. A growing tumor has also been
recognized to suppress the growth of its metastases (e.g., through release of angiostatin into circulation to
suppress angiogenesis at metastastic sites).
Radiation therapy uses ionizating radiation (X-rays, y-rays, protons, neutrons, ions) to shrink
tumors through damaging the DNA of cells. The method of delivery may be external (teletherapy) or
internal (brachytherapy). Similar to surgery, radiation therapy is localized; however, unlike surgery, the
anatomy is preserved. The extent of radiation therapy is limited by its teratogenic, mutagenic, and
carcinogenic effects, causing an increased risk of developing secondary leukemia and/or solid tumors.
Success of radiation therapy depends on the difference in radiosensitivity between tumor and normal
tissue. A major limitation for radiation therapy of solid tumors is deficiency in oxygen, a potent
radiosensitizer by formation of DNA-damaging free radicals, resulting in higher resistance to radiation
damage compared to surrounding healthy tissue with normal oxygen content.
Systemic chemotherapy is the main treatment available for metastatic, disseminated cancers. The
antineoplastic agents used are classified according to their cell cycle activity or their structure. Base on
cell cycle activity, these antineoplastic agents can be divided into three groups: Cell-cycle nonspecific
agents (kill proliferating or quiescent cells), cell-cycle specific/phase-nonspecific agents (kill proliferating
cells regardless of the cell phase), and cell-cycle specific/phase-specific agents (kill proliferating cells
only in a specific phase of the cell cycle). It should be noted that the distinction between the classes are
often relative. Additionally, the major antineoplastic agents can be classified based on their chemical
structure and mechanism of action into the following categories:
1. Alkylating agents (e.g. nitrogen mustards, alkylating-like agents such as cisplatin): form
covalent bonds and crosslinks with DNA (in particularly, guanine) and other biologically
important molecules.
2. Antimetabolites (e.g., folate analogs such as methotrexate, pyrimidine analogs such as 5-FU):
structural analogs of a naturally occurring metabolite involved in DNA synthesis.
3. Natural products (from plants, bacteria, and fungi; also synthetic and semisynthetic derivatives
of natural products)
a. Plant alkaloids (e.g., paclitaxel, docetaxel): interfere with microtubule function necessary for
cell division (cause disassembly or increased stability)
b. Antitumor antibiotics (e.g., the anthracyclines daunorubicin, doxorubicin, epirubicin):
Intercalates between DNA base pairs, inhibits topoisomerases, and/or formation of free
oxygen radicals that break DNA.
c. Topoisomerase inhibitors (e.g., topotecan, epipodophyllotoxins): Bind to and stabilize
DNA/topoisomerase cleavable complex, preventing religation of the DNA strand. A double-
strand break occurs when a replication fork encounters this cleavable complex.
Many antineoplastic agents (and also radiotherapy) function by damaging DNA and overwhelming the
capability of the DNA repair system, resulting in cell death. Normal cells have a greater ability to repair
minor DNA damage and continue living than cancer cells, thus these agents preferentially confer toxicity
toward the cancer cells. Furthermore, cell-cycle specific chemotherapeutics are most effective at killing
cells that are rapidly dividing (e.g., through interfering with cell division or DNA replication and function)
like cancer cells. However, they are also toxic toward fast-dividing normal cells such as those found in
the bone marrow (stem cells), digestive tract, hair follicles, etc. Certain drugs can also cause damage to
specific organs (e.g., cardiotoxicity by anthracyclins, ototoxicity by cisplatin). Consequently, a major
limitation of most chemotherapeutics are their narrow therapeutic index. The dosage is restricted by
normal tissue tolerance and is given at close to the maximum tolerated dose (MTD). For many drugs, this
dose is so low that the concentration of drugs that can be achieved in the tumor is below the therapeutic
level. Furthermore, chemotherapy drugs are oftentimes not delivered effectively throughout the entire
tumor in sufficient concentration due to physiological barriers (see section 1.3) and the cellular response
to the drug may also be spatially heterogeneous, resulting in eradication of cancer cells from some regions
but not others. Exposure of the cancer cells to sublethal concentration of the therapeutic agent may
facilitate the development of multidrug resistance (MDR) (18), in which tumor cells exposed to one
cytotoxic agent develops cross-resistance to a variety of other structurally and functionally unrelated
agents. MDR has been associated with at least two "pumps" that actively efflux drugs from the cell
interior, the two ABC transporters, P-glycoprotein and multidrug resistance-associated protein. Altogether,
these are some of the primary reasons that treatment of malignant cancer with chemotherapy often leads
to recurrence and is ultimately unsuccessful.
Most of the traditional chemotherapy drugs have been discovered empirically. However, in the last 35
years, an abundance of knowledge of the molecular alterations underlying cancer has been accumulated
and this knowledge has been applied to identifying and targeting specific molecules needed for
carcinogenesis. "Targeted Therapy" refers to rationally designing new drugs which target particular
molecules that has a critical role in tumor progression. Many of the current effort have been on kinases
and cell-surface receptors since they are druggable targets by small molecules and monoclonal antibodies.
Some prominent examples are:
1. Gleevac (imatinib mesylate): a small molecule inhibitor for the mutant protein Bcr-Abl
(associated with the Philadelphia chromosome) in chronic myeloid leukemia (CML) (19).
2. Avastin (Bevacizamab): a monoclonal antibody for VEGF, a ligand that promotes angiogenesis
(20).
3. Herceptin (Trastuzumab): a monoclonal antibody for Her2/neu (21), a growth factor receptor that
becomes constitutively active in some types of breast cancer.
1.3 Drug Transport in Solid Tumors
Tumor tissue can be divided into three compartments: the blood vessels (lymphatics are
nonfunctional), tumor cells, and the interstitial space (the space that surrounds the tumor cells). Systemic
delivery of therapeutics to solid tumors is a three step process: circulation of blood-borne drugs to the
tumor site through the blood vessels, transport across the vessel wall, and passage through the interstitial
space to reach the tumor cells. However, deliver of therapeutics is hindered by physiological barriers
imposed by the abnormal tumor vasculature and the dense interstitial matrix (IM), resulting in delivery of
heterogeneous and sublethal concentration of the drug in the tumor.
In systemic drug delivery, drugs are initially administered through oral, intravenous,
subcutaneous, intramuscular, or intraperitoneal injection. Except for intravenous, the drug is absorbed into
the blood and delivered to different organs throughout the body. The drug can be cleared from the body
mainly through the liver and kidney. Furthermore, the drug may be metabolized in the liver yielding an
inactive metabolite; in some cases, the metabolite is the active form. The rate that the drug is removed
from the blood influences the circulation half-life (time for the blood concentration to drop by a half of its
initial value) which may vary from seconds to days. During the time the therapeutic is in circulation, the
drug has an opportunity of being delivered into the tumor. The clearance of the drug from the body after
systemic administration and delivery to healthy tissue are major obstacles to tumor drug delivery.
1.3.1 Tumor vasculature
In normal vasculature, blood enters an organ in the order of large arterioles, small arteries,
arterioles, precapillary arterioles, and finally capillaries (the smallest vessels). The capillaries are
responsible for the exchange of nutrients and wastes between the blood and tissue. The blood leaves the
organ in the order of venules, small veins, and large veins. In the tumor, however, except for the large
arteries and vein, this tree-structured hierarchy does not exist. Tumor vessels are abnormal structures that
can be described as heterogeneous, tortuous, dilated, and irregularly shaped - defying simple
classification. Therefore, they are collectively known as tumor microvessels. This chaotic structure results
in heterogeneous blood flow and inefficient delivery of blood-borne substances into the tumor. Blood
flow velocity may vary both spatially and temporally with blood sometimes flowing backwards. In many
regions of the tumor, blood flow is slower than in normal tissue, resulting in decreased delivery of a
systemically administered drug into the tumor. Some of the tumor vessels are too small to allow red blood
cells to pass through and the average velocity of red blood cells can be an order of magnitude lower than
in normal tissue, both of which contributes to tumor hypoxia. In addition, tumor microvessels lack
smooth muscle cells on the blood vessel walls so that these vessels cannot react to vasoactive agents
which regulate blood flow in normal vasculature.
1.3.2 Transvascular transport
Once the therapeutics is in the tumor microcirculation, they may cross the vessel wall to enter the
tumor's interstitial space (22). The rate of transvascular transport for the drug can be modeled by the
Kedem-Katchalsky Equation (23):
JS = J'(1 - 0f)Cs + PS AC (1.1)
The first term is attributed to convective transport and the second term to diffusive transport (Fick's first
law). The rate of fluid flow across the microvessel wall J, can be modeled using Starling's law of
filtration:
J = LS(Ap - U-As) (1.2)
This equation states the rate of fluid flow across the microvessel wall is proportional to the hydrostatic
pressure difference Ap minus the osmotic pressure difference Am. Starling's law is equivalent to Darcy's
law ( v = -KVp) except the osmotic pressure gradient is also taken into account.
The constants are defined as follows:
v: fluid velocity
K: hydraulic conductivity. Equal to the Darcy permeability to the viscosity
Vp: gradient of the hydrostatic pressure
Ap: hydrostatic pressure difference across vessel wall
Arr: osmotic pressure difference across vessel wall
Ly: hydraulic conductivity of the vessel wall
S: surface area of the vessel wall
os: osmotic reflection coefficient. This term arises because the microvessel wall is permeable to the
separation of solutes that maintain the osmotic pressure difference.
ofg: filtration reflection coefficient.
Cs: average molar concentration of solutes in the vessel wall
P: microvascular permeability coefficient. Here, P is Deff/h, where h is the thickness of the vessel wall
AC: difference in concentration across the vessel wall
It is useful to note that JIS is the average velocity of fluid across the membrane per unit area.
In normal tissues, the transcapillary filtration and reabsorption of fluid back into the blood vessel
occurs according to Starling's law of filtration which depends on the hydraulic and osmotic pressure. The
small amount of fluid that is not reabsorbed back into circulation is taken up by lymphatic vessels, which
is driven by small shifts in the hydraulic and osmotic pressure. Thus in normal tissues, transport of drugs
can be due to both diffusion and convection. In neoplastic tissues, transvascular transport has three unique
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features. First, microvascular permeability is generally higher than in normal tissues due to the "leaky"
vasculature. But tumor vessel walls are "leaky" in some regions while not in others, which causes
heterogeneous perfusion of drugs. Second, the pores in the vessel wall have a higher cutoff size than in
normal tissues, allowing particles up to several hundred nanometers to extravasate into the tumor. The
liver sinusoids also allow large particles to extravasate but the cutoff size is only -100 nm. Third,
solid mechanical stress induced by the proliferating neoplastic cells in a confined space causes the
collapse of lymphatic vessels (24). The lack of functional lymphatics and the hyperpermeable vasculature
result in elevated levels of interstitial fluid pressure (IFP), which in turn reduces convective transport
across the vessel walls and into the interstitial space, leaving diffusion as the primary mode for
transvascular drug transport.
1.3.3 Interstitial Transport
After crossing the vessel wall or after local administration, the drug must pass through and react
with components in the tumor's interstitial space. This region is made up of the interstitial fluid -
consisting of nutrients, wastes, growth factors, inhibitors, etc. - and the extracellular matrix - a complex
assembly of collagens, elastins, glycoaminoglycans, proteoglycans, and structural glycoproteins. The
constituents of the interstitial fluid are similar to those in the plasma except for lower concentrations of
oxygen and glucose. Transport across the interstitial space is one of the most difficult steps in drug
delivery to tumor cells due to several unique characteristics of solid tumors at the molecular, cellular, and
tissue level (23). First, as mentioned previously, low convective transport through the interstitial space
leaves diffusion as the primary mode for both transvascular and interstitial transport. In normal tissues,
diffusion has been found to be dominant for small therapeutics and convection to be more significant for
larger therapeutics like monoclonal antibodies, viruses, and nanoparticles (since diffusion is highly size
dependent). Therapeutics larger than 60 nm are not able to effectively diffuse in the interstitial space due
to the dense collagen matrix. Because diffusion is the primary mode for transport in the interior of the
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tumor, interstitial transport is especially difficult for the delivery of larger therapeutic agents. Second, the
pressure gradient drops off precipitously at the tumor margin, causing a convective flow of drugs (along
with excess fluid, macromolecules, and tumor cells) to seep out of the tumor periphery and be collected
by the lymphatic vessels in the tumor margin and surrounding normal tissue, reducing drug delivery to
tumor cells. Third, due to the heterogeneous perfusion of tumor vessels, drugs need to diffuse large
distances to reach hypo-vascular regions of the tumor. Fourth, binding (e.g. to DNA, extracellular matrix),
sequestration (e.g. in endosomes), and metabolism of drugs hinder the transport of therapeutic agents in
the interstitial space.
Drug transport in the tumor in the interstitial space can be depicted as solute transport in porous
media filled with discrete obstacles to diffusion - the tumor cells. A complete physical description of
diffusion through the interstitial space is exceedingly cumbersome. Effective diffusion coefficients are
often used to estimate rates of transport in these situations. The increase in path length induced by
physical obstacles in the interstitial space can be described by the tortuosity. Tortuosity is defined as the
ratio of effective path length (L, shortest distance between two points through the obstacles) to linear path
length (L0, shortest distance between the same two points disregarding the obstacles): r = L/LQ. The
variables of concern are defined below:
Deff: effective diffusion coefficient measured in tissue
D1,t: interstitial diffusion coefficient
D,: diffusion coefficient in free solution
r: tortuosity
Tg: geometric tortuosity
Tv: viscous tortuosity
The Stokes-Einstein relation can be used to determine the diffusion coefficient of an agent in free
solution assuming it has a spherical configuration:
Do = kBT (1.3)
67ltyRH
where kB is Boltzmann's constant, kB= 1.38 x 1023 J/deg, T is temperature in K, i is the viscosity of
water, and RH is the hydrodynamic radius. The diffusion coefficient measured in tissue is related to the
diffusion coefficient in free solution by the tortuosity (25, 26):
Deff = Do (1.4)
The tortuosity is a result of contributions from cellular obstacles and matrix molecules: T = Tg T,.
The geometric tortuosity (Tg) is due to the geometric effects imposed by the organization of tumor cells
which can hinder long range diffusion of smaller therapeutics. The viscous tortuosity (T,) is due to the
frictional effects induced primarily by the dense collagen matrix which assumes greater importance when
the size of the therapeutic agents becomes comparable to the dimensions of the channel through which
they have to traverse. The diffusion coefficient in the interstitial space Dint is related to diffusion in free
1
solution through: Dint = 1D 0 .
1.4 Nanomedicine for Cancer Therapy
An ideal drug-delivery system possesses two properties: the ability to target and to control the
release of drugs. Targeting will ensure the drug is delivered to the tumor with high efficiency and adverse
effects in normal tissues are reduced. Targeting is especially important for anticancer drugs, which are
also cytotoxic toward normal cells. Controlled release can also reduce or prevent adverse affects.
Nanocarrier delivery systems have provided new tools for the delivery of therapeutics that can facilitate
transport to the tumor and provide controlled release. Specifically, the advantages of nanocarrier delivery
systems may include (27):
1. Enhanced Permeation and Retention (EPR) Effect: Because the cutoff size of pores in the tumor
vessel wall is generally higher than vessel walls found in normal tissues, nanotherapeutics are
able to preferentially accumulate in the "leaky" regions of tumor vasculature more than in normal
tissue due to their large size compared to much smaller therapeutics, thus reducing normal tissue
toxicity. Furthermore, the lack of functional lymphatics in the tumor interior hinders clearance of
the drug from the tumor. All these factors contribute to the phenomenon known as the EPR effect
(28).
2. Delivery of hydrophobic drugs.
3. Co-delivery of two or more therapeutics for combination therapy.
4. Co-delivery of therapeutics with imaging modalities for simultaneous visualization of sites for
drug delivery.
5. Delivery of large macromolecules into cells.
6. (Active) targeted delivery of therapeutic to the cell/tissue of interest.
7. Protect drugs from binding (to cancer cells or components in the tumor microenvironment),
metabolism (degradation), and sequestration.
8. Increase blood circulation time.
9. Controlled drug release.
10. Improved dose scheduling for higher patient compliance.
However, nanotherapeutics also adds to the list of challenges in developing, manufacturing, and
gaining regulatory approval of anticancer drugs. The following are several characteristics that are
advantageous in designing a nanocarrier drug delivery system (29):
1. The active pharmaceutical ingredient (API) comprises a high weight fraction (loading) of the
total nanocarrier system (for example, at least 30%).
2. A large fraction of API used in the first step of the encapsulation process is incorporated into the
final carrier (entrapment efficiency).
3. The nanoparticles (NP) can be freeze-dried and reconstituted in solution without aggregation.
4. Biodegradable.
5. Small size. Typically ~100 nm or less for passive tumor targeting and greater than -6 nm to avoid
renal clearance.
6. Characteristics to prevent rapid clearance of the particles from the bloodstream (e.g., a "stealthy"
surface to prevent clearance by the reticuloendothelial system or RES).
A nanoparticle drug delivery system needs to exhibit the above characteristics to a large extent.
To date, over twenty nanotherapeutics have been FDA-approved for clinical use. These products
are dominated by liposomal drugs and polymer-drug conjugates. Examples of FDA-approved
nanoparticle-based therapeutics for solid tumors include Doxil@ (~100 nm PEGylated liposomal form of
doxorubicin), Abraxane@ (~130 nm albumin bound paclitaxel nanoparticle), and DaunoXome@ (a 40-60
nm liposomal form of daunorubicin). Despite lower toxicity to normal tissues such as reduced
cardiotoxicity in the case of Doxil@, nanotherapeutics still have adverse affects such as palmar-plantar
erythrodysesthesia for Doxil® and sensory neuropathy and nausea for Abraxane@.
In the case of the paclitaxel nanosuspension Abraxane®, the nanoparticle formulation of
paclitaxel provides several significant advantages over the Cremophor-based formulation Taxol®.
Paclitaxel is a very hydrophobic molecule and has been formulated with Cremophore EL and ethanol in
order to be given to humans. However, Cremophore EL has been associated with a host of problems
including hypersensitivity (requiring premedication such as antihistamines and the steroid
dexamethasone), long infusion time (3 hrs), and leaching of plasticizer from IV tubing. On the other hand,
Abraxane@ is a formulation of paclitaxel that uses only human serum albumin, a natural carrier for
hydrophobic molecules, without the need for any solvents. No premedication is necessary and the drug is
given only over 30 minutes with standard IV tubing. Transmission electron microscopy (TEM) of
Abraxane@ shows a core consisting of paclitaxel, surrounded by an albumin shell. The diameter ranges in
size from 100 to 200 with an overall mean size of 130 nm. The zeta potential is -31 mV. It is
manufactured by adding a solution of methylene chloride solution containing paclitaxel to an aqueous
solution of human serum albumin under low speed homogenization, creating an emulsion (30). The
albumin migrates to the interface between the water and methylene chloride of the emulsion. High-
pressure homogenization is applied to reduce the size of the particles and stabilize the particles through
disulfide bond cross-linking. The methylene chloride is then volatilized and the suspension is sterile-
filtered. The resulting aqueous suspension of nanoparticles consists of an amorphous paclitaxel core
coated with a 25 nm thick shell of paclitaxel-bound albumin. The size of the albumin nanoparticles is
highly concentration dependent. The nanoparticles are initially 130 nm at high concentration (in the
original vial). But as the concentration is reduced in plasma, the size very rapidly decreases to 10-15 nm
albumin particles.
The Table 1.1 provides a comparison of the pharmacokinetic properties between Abraxane@ and
Taxol@. The maximum drug concentration Cmax is higher for Abraxane@ because it is given over 30
minutes instead of 3 hours. The reduced area-under-the-curve (AUC) or overall amount of drug in the
blood after a dose for Abraxane® has been attributed to faster partitioning out of the vascular
compartment. In the case of Taxol®, Cremophor micelles are bound very strongly to paclitaxel, reducing
the amount of free paclitaxel in the plasma available for partitioning into the tissue compartment from the
central blood compartment. Abraxis BioScience, the company behind Abraxane®, has claimed that
Abraxane@ can enhance tumor delivery by exploiting the endogenous albumin pathways SPARC
(secreted protein acidic rich in cysteine) and endothelial transcytosis via albumin-mediated gp60 receptor.
Drug/dose Com (ng/mL) AUCo-1o tr2(hr) Cl (L/hr/m 2)
{ngr/n
Abraxane (135 mg/m2/ 6100 6427 15 21
30min)
Taxol (135 mg/m 2/3 hr) 2170 7952 13 18
Table 1.1. Pharmacokinetics comparison between Taxol@ and Abraxane@
Nanotherapeutics like Abraxane@ and Doxil® have resulted in reduced adverse effects in normal
tissues but have provide only modest survival benefits (31-33). This sub-optimal outcome is likely
attributed to the physiological barriers imposed by the abnormal tumor vasculature and the dense
interstitial matrix which hinder delivery of the drug throughout the entire tumor in sufficient
concentration (34, 35).
As previously mentioned, systemic delivery of therapeutics to the tumor is a three step process:
blood-borne delivery to different regions of the tumor, transport across the vessel wall, and passage
through the interstitial space to reach the tumor cells (36). Abnormalities in the tumor vasculature lead to
highly heterogeneous vascular perfusion throughout the tumor. The microvascular density is high at the
invasive edge of the tumor but sometimes the tumor center is unperfused, preventing delivery of
therapeutics to this region. However, the tumor center's hostile microenvironment (low pH and low PO2)
harbors the most aggressive tumor cells and the tumor will regenerate if these cells are not eliminated.
Moreover, exposure of the cancer cells to sublethal concentration of the therapeutic agent may facilitate
the development of resistance.
Hyper-permeability of the abnormal vasculature and lack of functional lymphatics lead to
elevated levels of interstitial fluid pressure (IFP) (37, 38). This interstitial hypertension in turn reduces
convective transport across the vessel wall and into the interstitial space, leaving diffusion as the primary
mode for drug transport to the poorly perfused regions. Large 100-nm nanotherapeutics such as Doxil®
are suitable for the EPR effect (39) but have poor diffusion in the dense collagen matrix of the interstitial
space (40, 41), resulting in restrictive nanoparticle accumulation around tumor blood vessels and little
penetration into the tumor parenchyma. In the case of Doxil@, the liposomal particles are trapped close to
the tumor vasculatures. Although the small size (~400 MW) of doxorubicin, which is released from the
liposomes, seemingly allow rapid diffusion, doxorubicin cannot migrate far from the particles due to avid
binding to DNA and sequestration in acidic endosomes of perivascular tumor cells (42, 43), resulting in
heterogeneous therapeutic effects.
1.5 Multistage Nanoparticle Delivery System
To navigate through the multiple obstacles preventing effective drug delivery to solid tumors, we
propose a multi-stage approach in which nanoparticles change their size to facilitate transport by adapting
to each physiological barrier. The multistage nanoparticles are originally ~100 nms and preferentially
extravasate from the leaky regions of the tumor vasculature. After extravasation into tumor tissue, the
nanoparticles "shrink" to 10 nm, significantly lowering their diffusional hindrance in the interstitial
matrix (25) and allowing penetration into the tumor parenchyma. These smaller nanoparticles can
potentially be used as nanocarriers for therapeutics that are released as the particles penetrate deep into
the tumor (Figure 1.1). Surface PEGylation of the small nanoparticles allows them to diffuse smoothly in
the interstitial matrix by reducing the binding, sequestration, and metabolism that hinder the transport of
therapeutic agents (44, 45). Furthermore, 10-nm nanoparticles are not cleared from the tumor as rapidly as
much smaller molecular species due to their larger size.
To achieve this size shrinking property, a large nanoparticle should be triggered to release smaller
nanoparticles after extravasation into the tumor. Several nanoparticles have been designed to release their
contents remotely via an external stimulus (light, heat, ultrasound, magnetic field, etc.), but their use to
date has been limited to local therapy. Systemic therapy is necessary to treat the metastases, which are the
major cause of cancer mortality. Water hydrolysis- (29), diffusion-, or solvent-controlled release
mechanisms can achieve systemic effects but do not give preferential release in the tumor, resulting in
increased toxicity in normal tissues. To attain both systemic therapeutic effects and preferential release in
tumor tissues, we aim to trigger the size change using an endogenous stimulus characteristic of the tumor
microenvironment, such as low pH, low partial oxygen pressure, or high concentrations of matrix
metalloproteinases (MMPs). Acidic and hypoxic regions tend to be far from blood vessels (46), not in the
perivascular regions where the large nanoparticles are trapped. MMPs, particularly gelatinases A and B
(MMP-2 and -9), are key effectors of angiogenesis, invasion, and metastasis including the epithelial-
mesenchymal transition (EMT), a cell-biological program which executes many of the steps of the
invasion-metastasis cascade. They cleave away the extracellular matrix (ECM), creating space for the cell
to move and releasing sequestered growth factors (47, 48). Levels of MMP-2 and -9 are high at the
invasive edge of tumors and at the sites of angiogenesis - regions the large nanoparticles are likely to
extravasate. These conditions make enzymatic degradation by MMPs a highly favorable trigger
mechanism.
Because both MMP-2 and -9 are extremely efficient at hydrolyzing gelatin (denatured collagen),
we engineered a 100-nm nanoparticle with a core composed of gelatin and a surface covered with
quantum dots (QDs), a model 10-nm nanoparticle. Gelatin nanoparticles have been shown to have a long
blood circulation time and high accumulation in tumor tissues (49), properties necessary for the first-stage
NP carrier. In order to access the spatial and temporal distribution of the nanoparticles in the tumor milieu,
we used -10 nm QDs as a stand-in for therapeutic nanocarriers, so that the nanoparticles' distribution in
vivo can be imaged using time-lapse multiphoton microscopy. Compared to traditional organic
fluorophores, QDs have high resistance to photo- and chemical-degradation, narrow photoluminescence
spectra, broad excitation spectral windows, and large two-photon absorption cross-sections - enabling the
use of multiphoton microscopy to image deep into the tumor with high spatial resolution (50).
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Figure 1.1 Schematic depiction of the multistage nanoparticle drug delivery system. The initial 100-nm
multistage nanoparticle delivery system accumulates preferentially around leaky vessels in tumor tissue.
Due to its large size, the 100-nm nanoparticle cannot penetrate the dense collagen matrix of the interstitial
space. However, endogenous MMPs can proteolytically degrade the gelatin core of the 1 00-nm
nanoparticle, releasing smaller 10-nm nanoparticles from its surface, which can penetrate deep into the
tumor due to their small size and PEGylated ("stealthy") surface. After disseminating all through the
tumor, the 10-nm nanoparticles can serve as depots for drugs that are released uniformly throughout the
tumor.
1.6 Quantum Dots in Biological Applications
Fluorescence tagging in the life sciences has traditionally relied on organic fluorophores and
fluorescent proteins for tracking or analyzing biological molecules by means of their fluorescent emission
at a specific frequency. However, these species suffer from narrow excitation range, broad emission
spectra, tendency for photobleaching and chemical degradation that limit their uses in bioimaging and
sensing. Semiconductor nanocrystals or quantum dots (QD) possess certain properties that offer
advantages over their organic counterparts in certain bioapplications. They possess broad excitation
spectral window that span from the band edge to the UV region, allowing multiplex imaging through the
ability to excite QDs with multiple narrow emissions using a single excitation wavelength. By tuning the
size of the QD and using different materials, the emission wavelength of the QD can be tuned from the
visible to the near infrared wavelengths. In addition, their large two photon absorption cross section
enables their use in multiphoton microscopy for deep imaging with high resolution. QDs have been
conjugated to various biomolecules such as peptides, proteins, DNA, etc. for applications in imaging,
sensing, and diagnostics.
1.6.1 Basic Properties
Semiconductor nanocrystals (QDs) are small solution-grown clusters of atoms that are - 1-10 nm
in size. Their shapes can be spherical, cubic, rod-like (51), triangular, etc. These materials exhibit unique
electronic properties different from their bulk counterparts that are attributed to the quantum confinement
effect. The quantum confinement effect occurs when the size of the nanocrystal becomes comparable to,
or smaller than, the size of the bulk Bohr exciton radius. This effect results in the widening of the
effective energy band gap with decrease in nanoparticle size that causes a blue-shift in the first absorption
peak and the photoluminescence spectrum. Quantum confinement also results in discrete energy states of
higher energy in the valence and conduction band. This phenomenon can be understood by a simple
extension of the one-dimensional particle in a box model to a three-dimensional (or spherical) model
where the box represents the QD and the barrier represents the abrupt interface at the QD surface. For a
one-dimensional box with infinite barrier and length L, the carrier confinement results in discrete energy
levels that are spaced at
En oc , with n = 1,2,3 ... (1.5)
In the case of a spherical energy barrier with radius a0, the energy levels for the electron and hole
can be written as (52):
El' - n (1.6)1,n 2meha2
Where f#i,n is the nth root of the spherical Bessel function of order I (solution obeying the
boundary condition), me,h is the effective mass of the electron (e) or hole (h), and aois the radius of the
QD. The confinement results in discrete quantized exciton transitions and an increase in the effective
band gap energy with decreasing particle size, which is expressed as
Eg(QD) = Eg (bulk) + 2 (1-7)2
me,hao
It should also be mentioned that these energy levels are also affected by the Coulomb interaction
between the confined carriers. However, this term has a weaker dependence on size (1/a, dependence
instead of 1/a,) so the contribution is small and often treated as a perturbation on the energy values. The
relationship between size and spectral shifts in the absorption and fluorescence peaks for CdSe quantum
dots has been relatively understood.
Colloidal QDs have also been discovered to exhibit intermittent on/off photoluminescence
(blinking) (53). This property has been attributed to Auger recombination though the phenomenon is not
fully understood. Recently, QDs have been shown to be non-blinking by overcoating with a thick CdS
shell (54).
1.6.2 Synthesis and Characterization
Solution-phase growth of semiconductor nanocrystals was first carried out within inverse
micelles. This approach uses the natural nanoscale structures created by water-in-oil mixtures upon
adding an amphiphilic surfactant such as sodium dioctyl sulfosuccinate (AOT), cetyltrimethylammonium
bromide (CTAB), and tetraoctylammonium bromide (TOAB). The size of the water-in-oil droplets can be
controlled by varying the water content. Metal salts are added to the solution and they migrate to the
water droplets, initiating nucleation and growth. However, this method did not produce QDs with good
crystalline structure and high quantum yield that is necessary to transition to biological applications.
A major breakthrough occurred in 1993 when Bawendi and coworkers showed that high quality
nanocrystals can be synthesized using an organometallic approach based on the pyrolysis of metal-
organic precursors (55). This approach yielded QDs with crystalline core, narrow size distribution (~10
percent), and relatively high quantum yield. The synthesis typically used dimethylcadmium (CdMe2) and
trioctylphosphine selenide (TOP-Se) diluted in trioctylphosephine (TOP) and injected into a coordinating
solution of trioctylphosphine oxide (TOPO) at 280-300'C. The size distribution can be further improved
using size selective precipitation. This synthetic method improved the QD's quantum yields to 5-10%
enabling fundamental fluorescence-based studies and research in technological applications.
Peng and coworkers later used less volatile, pyrophoric, and hazardous precursors than CdMe2 to
effectively prepare high-quality nanocrystals (56). They and other groups also pointed out the importance
of impurities such as hexylphosphonic acid (HPA) and tetradecylphosphonic acid (TDPA) in coordinating
to the metal precursors and controlling the reaction kinetics. In this method, high quality Cd-based
nanocrystal was synthesized using high purity TOPO, controlled amounts of metal coordinating ligands,
and more benign metal precursors such as CdO, cadmium acetate (Cd(OAc)2), cadmium hydroxide
(Cd(OH) 2), and cadmium acetylacetonate (Cd(acac) 2). Murray and coworker showed that near-infrared
PbSe QDs can also be synthesized using a high temperature synthetic route with oleic acid, TOP:Se, and
Lead(II) acetate trihydrate or lead oxide (57, 58).
Precipitation involves addition of a nonsolvent of the QD (methanol, ethanol, acetone, etc) into
the QD solution. Centrifugation of the precipitated solution followed by removal of the supernatant
purifies the solution of left over reagents from the synthesis and excess ligands. Size selection of the QD
sample can be performed by tuning the amount of the nonsolvent added such that only the larger fraction
of the QD population precipitates. When using less reactive precursors, precipitation is essential in
removing impurities and various metal-coordinating molecules since large amounts of unreacted material
are left over in the QD gross solution.
Overcoating the QD with a layer of higher band gap material can passivate the QD surface which
greatly improves the quantum yield and stability of the nanocrystal. In 1996, Hines and Guyot-Sionnest
overcoated CdSe QDs with ZnS to improve the quantum yield up to >30% (59). Air-stable precursors
have also been applied to overcoating as in the case of core synthesis. After overcoating, the absorption
and fluorescence spectra red shifts and both the absorption and emission peaks usually broaden. The red-
shifting is higher for lower band gap shell material (CdSe vs ZnS) and is attributed to leakage of the
exciton wavefunction into the shell layer because of the shell's finite barrier height. The spectral
broadening is caused by broadening in the size distribution that occurs during the overcoating step carried
out at high temperature. A smaller lattice mismatch in the core and shell material results in less lattice
strain at the interface and enables higher quality epitaxial growth of shell material.
General QD characterization techniques include high and low resolution transmission electron
microscope (TEM), wide angle X-ray diffraction (XRD), small angle X-ray scattering (SAXS), ICP-OES,
absorption, and fluorescence spectroscopy. These measurements can be used to obtain the size,
distribution width, crystal structure, band edge value, emission energy level, and quantum yield of the QD
sample.
1.6.3 Water-Solubilization Strategies
QDs can be made water soluble by directly synthesizing them in aqueous solution using inverse
micelle or co-precipitation as shown for CdTe QDs. However, these synthesis methods have not produced
high enough quality QDs that could be used for in vivo applications. QDs prepared using high
temperature synthesis routes capped with TOP/TOPO (also with amines and/or acid molecules) have been
one of the main methods for synthesizing QDs used for in vivo biological applications. Synthesis routes
utilizing TOP/TOPO produces an outer layer of hydrophobic ligands after synthesis which makes it
necessary to develop water solubilization strategy for transfering the QD to aqueous solution. These
strategies can be roughly divided into ligand-exchange and encapsulation.
Ligand exchange involves replacement of the original hydrophobic surface ligands with
hydrophilic surface ligands. The hydrophilic ligand is composed of anchor group(s) that bind to the QD
surface (typically by thiol or imidazole) and hydrophilic group(s) that render the QD water soluble (PEG,
amine, carboxyl). The most basic ligands are monothiol alkyl carboxylic acids such as cysteine (60),
mercaptoacetic acid (MAA), mercaptopropionic acid (MPA), mercaptoundecanoic acid (MUA), and
poly(ethylene glycol) (PEG) derivatives of these ligands. Cap-exchanges involving these ligands are
simple but the resulting QDs are usually unstable in aqueous solution and end up aggregated within a day.
The fluorescence quantum yield also decreases due to decrease in surface passivation and aggregation.
This instability is due to desorption of the ligand from the QD surface. This problem can be alleviated by
using bidentate-thiol ligands such as dihydrolipoic acid (DHLA) (61). DHLA-capped QDs can be stable
in aqueous solution for a week. However, DHLA-capped QDs and other carboxyl-terminated QDs are
only stable at basic pH due to protonation of the carboxyl groups at low pH and thus loss of surface
charge. This problem can be prevented by the use of PEGylated derivatives that allow for stability at a
wide range of pH (62). Additionally, the terminal end of the DHLA-PEG ligand can be functionalized
with amine, carboxyl, biotin, etc. for further bioconjugation reactions (60). This method provides a
functional and modular approach to bind to bio-molecules through biotin-streptavidin or sulfo-NHS (N-
hydroxysulfosuccinimide)/EDC (1-Ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride)
coupling chemistry.
A related technique for water solubilization developed by Weiss and coworkers (63) uses a
peptide with multiple cysteines for multidentate binding with the QD surface. The advantage of this
technique is that the peptide can be designed using standard Fmoc peptide chemistry to have different
lengths and functional groups. In addition, a peptide sequence can be directly built in for biological
targeting. The disadvantages are that peptide synthesis is relatively expensive and large amounts of
peptides are necessary for cap exchange.
Alivisatos and coworkers first introduced the use of QDs for biology by coating the QD with a
layer of silica which can then be functionalized using silane precursors (64). The QDs are first cap-
exchanged with a thiol-terminated silane ligand, and then the shells are cross-linked to promote stability.
This strategy, however, is time consuming and control of the shell growth is difficult.
Kim et al. developed an oligomeric phosphine ligand composed of an inner layer of oligomeric
phosphine for passivation of the QD surface and an outer layer of carboxylic acid or PEG for water
solubilization (65). However, this approach requires tedious synthesis and purification of the ligand.
Other groups have used similar multidentate approaches that use polymers with multiple amines for
binding to the QD surface such as polyethyleneimine and poly(ethylene glycol-b-2-N,N-
dimethylaminoethyl methacrylate) (PEG-b-PDMA). Liu et al. later developed a polymer synthesized
using RAFT polymerization chemistry with multiple imidazole groups for binding to the QD surface and
PEG for water solubilization (66). The multidentate binding with imidazole allowed for high stability
compared to thiol-based ligands and was demonstrated to be stable in PBS at room temperature for
months. However, due to the protonation of imidazole at low pH, the resulting QDs are not stable below
pH ~6. Another disadvantage is that functionalization with amine-PEG results in the amines binding on
the QDs' surface instead of being exposed and available for bioconjugation. EDC-coupling of the QDs to
biomolecules produces low conjugation yields.
Another method for water solubilization is encapsulation within an amphiphilic molecule, such as
block copolymer shells and phospholipid micelles (67). These amphiphilic molecules contain
hydrophobic segments that interdigitate with the TOP/TOPO shell and hydrophilic units that impart
dispersion in aqueous solution. Di- and tri-block copolymers have been used as the amphiphilic coating
shell for QDs. These molecules usually contain a polyacrylic acid backbone and substitution of some of
the carboxyl groups with alkyl chains. A balance between the hydrophilic and hydrophobic groups on the
surface is necessary for stability in water. Wu et al. (68) have used a 40% octylamine-modified
polyacrylic acid which is currently used in the commercial QDs sold by Invitrogen. Pellegrino et al. (69)
have used a poly(maleic anhydride alt-i -tetradecene) for water solubilization. This polymer is first
absorbed onto the surface of the QD and then bis(6-aminohexyl)amine is applied to cross-link the
polymer for enhanced stability. The anhydride groups are then hydrolyzed for water solubilization.
Dubertret et al. reported another approach that uses phospholipid derivatives to form a micelle around the
QD (67). They first used a mixture of 40% 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-
[methoxy(polyethylene glycol)-2000] (mPEG-2000 PE) and 60% 1,2-dipalmitoyl-sn-glycero-3-PC.
However, this approach requires rather expensive phospholipids, suffers from instability at low
concentrations, and each micelle may contain more than one QD.
The various surface functionalization strategies have strengths and weaknesses that make each of
them suitable for different applications. The cap-exchange methods tend to produce the most compact
QDs but they suffer from a lower quantum yield (QY) because their original ligand shell has to be ripped
off and replaced. Whereas, encapsulation methods tend to produce QDs with higher QY due to the
preservation of their original TOP/TOPO ligand coating but their hydrodynamic diameter tend to be
larger. Applying QDs for a certain biological application require careful assessment of the advantages and
drawbacks of different water-solubilization strategy.
1.6.4 Bio-Conjugation Strategies
There are four main approaches to conjugate molecules to water soluble QDs: EDC/sulfo-
NHS/SMCC coupling, biotin-avidin(streptavidin) binding (K ~ 10-" M), metal-affinity driven self
assembly of polyhistidine/thiolated peptides (70) and engineered proteins on the QD surface (K- 10-4-10-
8 M), and tetracene-neoborene coupling (71). Each of these methods has strengths and weaknesses. EDC
coupling usually does not require further modification of the bio-molecule. However, this method may
cause aggregation for carboxyl coated QDs (72). Metal-affinity driven self assembly of polyhistidine
peptides is based on the high affinity of polyhistidine toward the Group II elements (Cd, Zn) on the QDs'
surface. This method have high conjugation efficiencies that allow some control over the valency of
bound peptides but they are limited to cap-exchanged QDs that allow accessibility of the polyhistidine on
the QD surface such as DHLA-based and monothiol ligands. Biotin-avidin binding is highly efficient,
stable, and specific but require conjugation of either biotins or avidins to the biomolecules first. The
avidin or streptavidin also adds to the size of the QD-conjugate. Tetracene-neoborene coupling exhibits
high specificity but requires a relatively tedious synthesis procedure.
1.7 References
1. L. Zitvogel, A. Tesniere, G. Kroemer, Nature Reviews Immunology 6, 715 (2006).
2. D. Hanahan, R. A. Weinberg, Cell 100, 57 (2000).
3. D. J. Slamon et al., Science 235, 177 (1987).
4. G. J. Hannon, D. Beach, Nature 371, 257 (1994).
5. A. 0. H ueber et al., Science 278, 1305 (1997).
6. H. Symonds et al., Cell 78, 703 (1994).
7. L. Hayflick, Biochemistry-Moscow+ 62, 1180 (1997).
8. C. M. Counter et al., Embo J 11, 1921 (1992).
9. T. M. Bryan, A. Englezou, J. Gupta, S. Bacchetti, R. R. Reddel, Emboi 14, 4240 (1995).
10. K. J. Kim et al., Nature 362, 841 (1993).
11. P. Carmeliet, R. K. Jain, Nature 407, 249 (2000).
12. G. Bergers et al., Nat Cell Biol 2, 737 (2000).
13. F. G. Giancotti, E. Ruoslahti, Science 285, 1028 (1999).
14. A. E. Vernon, C. LaBonne, Curr Biol 14, R719 (2004).
15. G. Christofori, H. Semb, Trends Biochem Sci 24, 73 (1999).
16. J. D. Fackenthal, 0. 1. Olopade, Nature Reviews Cancer 7, 937 (2007).
17. A. J. Levine, Cell 88, 323 (1997).
18. P. Borst, R. Evers, M. Kool, J. Wijnholds, J Natl Cancer 192, 1295 (2000).
19. S. Chu, M. Holtz, M. Gupta, R. Bhatia, Blood 103, 3167 (2004).
20. N. Ferrara, K. J. Hillan, W. Novotny, Biochemical and Biophysical Research Communications 333,
328 (2005).
21. E. H. Romond et al., New EnglJ Med 353, 1673 (2005).
22. R. K. Jain, Cancer and Metastasis Reviews 6, 559 (1987).
23. G. A. Truskey, F. Yuan, D. F. Katz, Transport phenomena in biological systems. (Pearson Prentice
Hall, Upper Saddle River, N.J., ed. 2nd, 2009), pp. xxiii, 860 p.
24. A. J. Leu, D. A. Berk, A. Lymboussaki, K. Alitalo, R. K. Jain, Cancer Research 60, 4324 (2000).
25. A. Pluen et al., Proc Natl Acad Sci USA 98,4628 (2001).
26. S. Ramanujan et al., Biophysical Journal 83, 1650 (2002).
27. R. K. Jain, T. Stylianopoulos, Nature Reviews Clinical Oncology 7, 653 (2010).
28. H. Maeda, J. Wu, T. Sawa, Y. Matsumura, K. Hori, Journal of Controlled Release 65, 271 (2000).
29. R. Gref et al., Science 263, 1600 (1994).
30. D. Thassu, M. Deleers, Y. Pathak, Nanoparticulate drug delivery systems. (Informa Healthcare,
New York, 2007), pp. x, 352 p., [8] p. of plates.
31. E. P. Winer et al., Journal of Clinical Oncology 22, 2061 (2004).
32. W. J. Gradishar et al., J Clin Oncol 23, 7794 (2005).
33. M. E. R. O'Brien et al., Annals of Oncology: Official Journal of the European Society for Medical
Oncology / ESMO 15, 440 (2004).
34. R. K. Jain, Scientific American 298, 56 (2008).
35. R. K. Jain, Journal of Controlled Release 53, 49 (1998).
36. R. K. Jain, Annual Review of Biomedical Engineering 1, 241 (1999).
37. R. K. Jain, L. T. Baxter, Cancer Research 48, 7022 (1988).
38. Y. Boucher, L. T. Baxter, R. K. Jain, Cancer Research 50, 4478 (1990).
39. S. D. Perrault, C. Walkey, T. Jennings, H. C. Fischer, W. C. W. Chan, Nano Letters 9, 1909 (2009).
40. T. D. McKee et al., Cancer Res 66, 2509 (2006).
41. P. A. Netti, D. A. Berk, M. A. Swartz, A. J. Grodzinsky, R. K. Jain, Cancer Research 60, 2497 (2000).
42. Z. Ouar et al., Biochemical Journal 370, 185 (2003).
43. A. J. Primeau, A. Rendon, D. Hedley, L. Lilge, I. F. Tannock, Clinical Cancer Research 11, 8782
(2005).
44. R. K. Jain, Cancer Research 47, 3039 (1987).
45. A. 1. Minchinton, I. F. Tannock, Nat Rev Cancer 6, 583 (2006).
46. G. Helmlinger, F. Yuan, M. Dellian, R. K. Jain, Nat Med 3, 177 (1997).
47. R. Roy, B. Zhang, M. A. Moses, Experimental Cell Research 312, 608 (2006).
48. E. 1. Deryugina, M. A. Bourdon, R. A. Reisfeld, A. Strongin, Cancer Res 58, 3743 (1998).
49. G. Kaul, M. Amiji, Journal of Drug Targeting 12, 585 (2004).
50. M. Stroh et al., Nat Med 11, 678 (2005).
51. X. G. Peng, Advanced Materials 15, 459 (2003).
52. H. Mattoussi, J. Cheon, Inorganic nanoprobesfor biological sensing and imaging. Artech House
series engineering in medicine & biology (Artech House, Boston, 2009), pp. ix, 302 p., 21 p. of
plates.
53. M. Nirmal et al., Nature 383, 802 (1996).
54. Y. Chen et al., Journal of the American Chemical Society 130, 5026 (2008).
55. C. B. Murray, D. J. Norris, M. G. Bawendi, Journal of the American Chemical Society 115, 8706
(1993).
56. L. H. Qu, Z. A. Peng, X. G. Peng, Nano Letters 1, 333 (2001).
57. H. Du et al., Nano Letters 2, 1321 (2002).
58. W. W. Yu, J. C. Falkner, B. S. Shih, V. L. Colvin, Chem Mater 16, 3318 (2004).
59. M. A. Hines, P. Guyot-Sionnest, J Phys Chem-Us 100, 468 (1996).
60. W. Liu et al., Journal of the American Chemical Society 130, 1274 (2008).
61. A. R. Clapp, E. R. Goldman, H. Mattoussi, Nat. Protocols 1, 1258 (2006).
62. J. P. Zimmer et al., Journal of the American Chemical Society 128, 2526 (2006).
63. F. Pinaud, D. King, H. P. Moore, S. Weiss, Journal of the American Chemical Society 126, 6115
(2004).
64. D. Gerion et al., Journal of Physical Chemistry B 105, 8861 (2001).
65. S. Kim, M. G. Bawend i, Journal of the American Chemical Society 125, 14652 (2003).
66. W. Liu et al., Journal of the American Chemical Society 132, 472 (2010).
67. B. Dubertret et al., Science 298, 1759 (2002).
68. X. Y. Wu et al., Nat Biotechnol 21, 452 (2003).
69. T. Pellegrino et al., Nano Letters 4, 703 (2004).
70. H. Mattoussi et al., Journal of the American Chemical Society 122, 12142 (2000).
71. H. S. Han et al., Journal of the American Chemical Society 132, 7838 (2010).
72. H. Y. Shen, A. M. Jawaid, P. T. Snee, ACS Nano 3, 915 (2009).
49
50
Chapter 2
Synthesis and Characterization of
Size-Changing Nanoparticle Constructs
2.1 Introduction
We have established three main criteria for the multistage size-changing nanoparticle (NP): the
nanoparticles' size must change from 100 nm to 10 nm, their surface before and after MMP-2 cleavage
needs to be well PEGylated and neutral (to ensure the difference in transport before and after cleaving is
only a result of size change), and their sensitivity to cleavage should be at least as high as other reported
MMP-2 probes. Satisfying these three criteria simultaneously presented several design and synthetic
challenges. However, by optimizing the coupling scheme and the degree of glutaraldehyde cross-linking,
we were able to meet the desired criteria for this system while preserving the simplicity in design to
ensure scalability.
Since both the carrier and released nanoparticles need to be highly PEGylated and neutral. We
initialized used DHLA-PEG QDs, which had a relatively "sticky" surface (low coverage of PEG), and
allowed for encapsulation inside the core of 100-nm gelatin nanoparticle, but the particle after cleavage
showed a broad size distribution by gel filtration chromatography (GFC), indicating binding to
gelatin/glutaraldehyde fragments. An alternative strategy was to covalently attach the QDs onto the
gelatin NP surface. Though this approach is susceptible to interparticle cross-linking, through careful
optimization and utilizing EDC/sulfo-NHS chemistry to conjugate amino-PEG QDs to the carboxylic acid
groups on the gelatin NP surface, we produced nearly monodisperse QD-Gelatin NPs that released
cleaved QDs sans size increase.
By controlling the length and degree of glutaraldehyde polymerization used to cross-link the
gelatin nanoparticles, we were able to optimize the size of the QDs after cleaving and their rate of release
while maintaining particle stability. The method for gelatin nanoparticle synthesis developed in (1)
produced gelatin NPs with long extended networks of glutaraldehyde on their surface to maintain particle
stability in aqueous solution. However, when the same scheme was applied to our design, the QDs
remained covalently attached to this large glutaraldehyde polymer after MMP-2 degradation, resulting in
QDs that were significantly larger upon release. To produce released QDs without augmenting their size,
we constructed a network of numerous short cross-links on the gelatin particles instead. Since
glutaraldehyde readily self-polymerizes in solution, we used nearly monomeric glutaraldehyde (grade I)
for consistent formation of short glutaraldehyde polymer cross-links. In addition, using grade I
glutaraldehyde improved the MMP-2 cleaving rate considerably such that the release is as sensitive as
previously reported MMP-2 probes. By modifying the degree of cross-linking on the gelatin nanoparticle,
we optimized the QD-Gelatin NPs to be highly responsive to MMP-2 degradation while preserving
particle stability in storage for at least 48 days.
2.2 Materials and Methods
2.2.1 Materials
Gelatin type A ~175 bloom from porcine skin, glutaraldehyde solution (grade I, 50%), glutaraldehyde
solution (grade II, 25%), glutaraldehyde solution (no grade/grade X, 50%), N-Hydroxysulfosuccinimide
Sodium salt (sulfo-NHS), N-(3-Dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (EDC),
methoxypolyethylene glycol amine 5,000 (mPEG-amine 5 kDa), agarose, Collagenase from Clostridium
histolyticum Type I, Trysin 1Ox solution, at-lipoic acid, Tetraethylorthosilicate 99.999% (TEOS),
cyclohexane, polyoxyethylene (5) nonylphenylether (Igepal CO-520), and ammonium hydroxide (28% in
water), and Ethylenediaminetetraacetic Acid, Disodium Salt Dihydrate (EDTA) were purchased from
Sigma-Aldrich. Acetone, HEPES, and lOx PBS Liquid Concentrate were purchased from EMD
Chemicals Inc. (Gibbstown, NJ). Calcium chloride, isopropyl alcohol, and glycine were obtained from
Mallinckrodt Baker Inc. (Phillipsburg, NJ). Qdot@ 565 ITKTM amino (PEG) quantum dot and GIBCO@
Certified Heat-Inactivated Fetal Bovine Serum was obtained from Invitrogen (Eugene, Oregon). BlockTM
Casein in PBS was purchased from Thermo Scientific (Rockford, IL). Water was obtained using a
Barnstead NANOpure@ DIamond Life Science UV/UF TOC water system (Thermo Fisher Scientific,
Suwanee, GA). MethoxyPEG-silane (MW 5000 and 1000) were obtained from Laysan Bio Inc, silica
spheres 100 nm in diameter were purchased from Polysciences. Syntheses of water soluble PIL-coated
QDs and CdSe/CdS core/shell QDs are published elsewhere (2). All reagents were used as obtained
without further purification.
2.2.2 Synthesis of DHLA-PEG QD Peptide Silica Nanoparticles
QD-Silica Construct. The QD-silica constructs were obtained from Dr. Zoran Popovid (3). Prior to
synthesis procedure, the amount of QD to be added to silica spheres was estimated by DLS titration.
Aliquots of an aqueous stock solution of poly-imidazole-PEG (PIA)-coated QDs (2) (CdSe/CdS, 1-2 pM,
10 pL) were added to a stirred solution of a known amount of silica in water. After each addition step,
DLS measurements were performed up to the aliquot when the first change in size distribution by volume
was observed. The sum of added aliquots preceding the final addition was taken as a maximum loading
amount of QDs for that silica batch. On average 30-50x 101" moles of QDs in water per milligram of
silica spheres were added. In a typical synthesis experiment for 100 nm silica spheres, 10 mg of spheres
(178 pL of original 5.6% solution from Polysciences) were added to 10 ml water and sonicated for 10
min. To this solution, the previously determined quantity of PIA-coated QDs was added in 10 IL
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aliquots. Then, 15 ptL of TEOS and 50 pL of 28% aqueous ammonium hydroxide were added, followed
by 25 mg of amino-PEG5kDa-silane and 25 mg of methoxy-PEG5kDa-silane in 1 mL of water. The
vigorously stirred reaction mixture was kept at 70*C for 3.5 h and at RT for an additional 12 h after which
it was centrifuged three times from water at 10000 RPM for 25 min, dispersed in 5 mL of water,
sonicated, and passed through 0.45 pm filter. Obtained particles were stored at 4 C.
QD-Silica-Peptide Construct. We next conjugated the QD-Silica construct with a peptide
(HHHHHHGPLGLAGGGC) using sulfo-SMCC. The QD-Silica construct (50 pL of ~3 nM) was
incubated with 2 mg of sulfo-SMCC for 30 minutes. The QD-Silica-(sulfo-SMCC) conjugate was
centrifuged three times from water at 10000 RPM for 10 min and dispersed in ~300 tL of water. The
purified solution was then combined with 20 mg of the cleavable peptide and incubated for 30 minutes.
The QD-Silica-peptide conjugate was centrifuged three times from water at 10000 RPM for 10 min and
dispersed in ~300 pL of water each time.
QD-Silica-Peptide-QD Construct. The QD-Silica-Peptide construct was added slowly to a solution of
30 pL of -615 nm emitting DHLA-PEG QDs. The solution was allowed to incubate for 30 minutes. The
QD-Silica-peptide was centrifuged three times from water at 10000 RPM for 10 min and dispersed in
~300 pL of water.
2.2.3 Synthesis of DHLA-PEG QD Gelatin Nanoparticles
Gelatin nanoparticles were prepared from a modification of the two-step desolvation method
developed in (1). Gelatin type A (1.25 g) was added to 25 mL of DI water and heated at 45'C until
dissolution. The solution was then removed from heat and 25 mL of acetone was added to the solution at
12 mL/min while stirring slowly. After the acetone addition was completed, the stirring was turned off.
After exactly 30 seconds, the supernatant containing the low molecular weight gelatin fraction was
removed. DI water (25 mL) was added to the remaining precipitate and heated again to 40'C until
dissolution. 6 mL of the solution was removed and the pH of the removed fraction was adjusted to ~2.5
with HCl solution. A 25 tL of ~6 ptM solution of DHLA-PEG QDs was added to the gelatin solution.
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Under fast stirring and 45*C, 72 mL of acetone was added at 1 mL/min. After the acetone addition was
completed, 25 pL glutaraldehyde (no grade/grade X) was diluted in 500 pL of water and added to the
gelatin nanoparticles 25 pL at a time over about 3 minutes. Subsequently, the solution was kept at 40'C
and fast stirring for various times (from 1 hr to 12 hrs). The acetone was then rotavapped off slowly. The
remaining solution was filtered through a 0.2 im syringe filter. A solution of 1Ox PBS was added for a
final solution of~1x PBS with a pH of~7. Instead of centrifugation to purify the nanoparticles, we used
GFC to prevent aggregation and an increase in size. A 1 mL solution of the gelatin particles was injected
into a SuperoseTM 6 GL 10/300 column (GE Healthcare, Piscataway, NJ) with lx PBS as the mobile
phase. The peak eluting at the void volume was combined and concentrated using house vacuum very
gently. Amino-PEG (50 mg) was added into the DHLA-PEG gelatin particle solution along with EDC
(~10 mg). The solution was incubated for 3 hrs and purified again with GFC.
Gelatin in Dl water
acetone (12 mL/min),
remove supernatant
first desolvation
add DHLA-PEG QD
adjust pH to 2.7
High MW Gelatin
acetone (1 mUmin)
second desolvation
GFC
remove excess
glutaraldehyde MPEG5k-NH2
glutaraldehyde
cross linker
multiple additions
heat at 40degC, 2-10 hrs
GFC MMP-2
-) )
Figure 2.1 Synthetic Scheme for DHLA-PEG QD Gelatin Nanoparticles.
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2.2.4 Synthesis of Imidazole-PEG QD encapsulated Gelatin Nanoparticles
Gelatin nanoparticles were prepared from a modification of the two-step desolvation method
developed in (1). Gelatin type A (1.25 g) was added to 25 mL of DI water and heated at 450C until
dissolution. The solution was then removed from heat and 25 mL of acetone was added to the solution at
12.5 mL/min while stirring slowly. After the acetone addition was completed, the stirring was turned off.
After exactly 30 seconds, the supernatant containing the low molecular weight gelatin fraction was
removed. DI water (25 mL) was added to the remaining precipitate and heated again to 40'C until
dissolution. 6 mL of the solution was removed and the pH of the removed fraction was adjusted to -2.7
with HCl solution. A 25 ptL of ~6 tM solution of imidazole-PEG QDs was added to the gelatin solution.
The QDs' fluorescence was lost immediately after addition into the gelatin solution. Under fast stirring
and 400C, 72 mL of acetone was added at 1.5 mL/min. After the acetone addition was completed, 25 pL
glutaraldehyde (no grade/grade X) was diluted in 500 ptL of water and added to the gelatin nanoparticles
25ptL at a time over about 3 minutes. Subsequently, the solution was kept at 45'C and fast stirring for
various times (from 1 hr to 12 hrs). The acetone was then rotavapped off slowly. The remaining solution
was filtered through a 0.2 pm syringe filter. A solution of 1Ox PBS was added for a final solution of~1x
PBS with a pH of ~7. Instead of centrifugation to purify the nanoparticles, we used GFC to prevent
aggregation and an increase in size. A 1 mL solution of the gelatin particles was injected into a
SuperoseTM 6 GL 10/300 column (GE Healthcare, Piscataway, NJ) with lx PBS as the mobile phase.
2.2.5 Synthesis of Imidazole-PEG QD coated Gelatin Nanoparticles
Synthesis of Gelatin Nanoparticle. Gelatin nanoparticles were prepared from a modification of the two-
step desolvation method developed in (1). Gelatin type A (0.625 g) was added to 12.5 mL of DI water and
heated at 40'C until dissolution. The solution was then quickly removed from heat and 12.5 mL of
acetone was added to the solution at 6.0 mL/min while stirring at 300 rpm. After the acetone addition was
completed, the stirring was turned off. After exactly 1 min, the supernatant containing the low molecular
weight gelatin fraction was removed. DI water (12.5 mL) was added to the remaining precipitate and
heated again to 40'C until dissolution. Half the solution was removed and the pH of the remaining half
was adjusted to 2.7 with a 1 M HCl solution. Under constant stirring at 600 rpm and 40'C, 20.75 mL of
acetone was added at 1 mL/min. Following addition of ~17 mL of acetone, the solution appeared cloudy
white from the scattering by gelatin particles being formed. After the acetone addition was completed, 30
ytL of 50% glutaraldehyde solution (no grade/grade X) diluted in 1 mL acetone was added to the gelatin
solution at 0.05 mL/min to cross-link the particles. Subsequently, the solution was kept at 40'C and 600
rpm stir rate for 7.5 hours. The acetone was then rotavapped off slowly to a final volume of 5-6 mL. The
remaining solution was filtered through a 0.2 tm syringe filter. A 1 M glycine solution (0.2 mL) was
added and the solution was stored overnight at 4'C. Instead of centrifugation to purify the nanoparticles,
we used GFC to prevent aggregation and an increase in size. A 1 mL solution of the gelatin particles was
injected into a SuperoseTM 6 GL 10/300 column with 1x PBS as the mobile phase. The peak eluting at the
void volume was collected with 0.5 mL fractions. The first two concentrated fractions were combined.
This 1 mL solution was then taken to the next step for QD conjugation and PEGylation.
Synthesis of Imidazole-PEG QD coated Gelatin NPs. The 1 mL gelatin nanoparticle solution was
combined with 20 ptL of 8 uM Imidazole-amino-PEG QDs, and the solution was stirred at 130 rpm for 30
minutes. Afterwards, the pH was changed to 5 and then immediately adjusted to pH 6. Stirring continued
for 30 minutes. EDC (0.4 mg, 2.1 ptmol) and sulfo-NHS (0.4 mg, 1.9 pimol) was dissolved in 50 pL of DI
water and then added to the gelatin nanoparticle/QD mixture. The reaction proceeded for 3 hours. The
resulting mixture was filtered through a 0.2 ptm syringe filter and then purified using GFC with the
SuperoseTM 6 column. The mobile phase used was 50 mM HEPES buffer at pH 7.5 for subsequent in vitro
characterization of the QD Gelatin NP s or 1x PBS at pH 7.4 for subsequent in vivo experiments. The
peak eluting at the void volume was collected with 0.5 mL fractions and the first concentrated fraction
was used for further experiments.
2.2.6 Synthesis of Polyacrylic Acid-PEG QD-Peptide-Gelatin Nanoparticles
Synthesis of Gelatin Nanoparticle. Gelatin nanoparticles were prepared from a modification of the two-
step desolvation method developed in (1). Gelatin type A (0.625 g) was added to 12.5 mL of DI water and
heated at 40'C until dissolution. The solution was then quickly removed from heat and 12.5 mL of
acetone was added to the solution at 6.0 mL/min while stirring at 300 rpm. After the acetone addition was
completed, the stirring was turned off. After exactly 1 min, the supernatant containing the low molecular
weight gelatin fraction was removed. DI water (12.5 mL) was added to the remaining precipitate and
heated again to 40'C until dissolution. Half the solution was removed and the pH of the remaining half
was adjusted to 2.7 with a 1 M HCl solution. Under constant stirring at 600 rpm and 40'C, 20.75 mL of
acetone was added at 1 mL/min. Following addition of -17 mL of acetone, the solution appeared cloudy
white from the scattering by gelatin particles being formed. After the acetone addition was completed, 30
pL of 50% glutaraldehyde solution (grade X) diluted in 1 mL acetone was added to the gelatin solution at
0.05 mL/min to cross-link the particles. Subsequently, the solution was kept at 40'C and 600 rpm stir rate
for 5 hours. The acetone was then rotavapped off slowly to a final volume of 5-6 mL. The remaining
solution was filtered through a 0.2 pm syringe filter. A 1 M glycine solution (0.2 mL) was added and the
solution was stored overnight at 4'C. Instead of centrifugation to purify the nanoparticles, we used GFC
to prevent aggregation and an increase in size. A 1 mL solution of the gelatin particles was injected into a
SuperoseT M 6 GL 10/300 column with 1x PBS as the mobile phase. The peak eluting at the void volume
was collected with 0.5 mL fractions.
QD-peptide. A 45 pL of a 8 piM Qdot@ 565 ITKTM amino (PEG) QDs solution was mixed with sulfo-
SMCC (0.2 mg) in 0.5 mL of PBS solution. The sulfo-SMCC was fully dissolved first in PBS before
addition to QDs. The reaction was allowed to proceed for 30 minutes and then the solution was dialyzed
2x with a 50 kDa spin dialysis filter. The cleavable peptide linker (0.267 mg) was then added (1000x fold
excess) and allowed to react for 2 hours. The solution was again dialyzed 2x with a 50 kDa spin dialysis
filter to remove excess peptides.
QD-peptide Gelatin construct. The QD-peptide construct from the previous step was added to 200 pL of
Gelatin NP after the first GFC purification. The pH was adjusted to -6 and then 0.45 mg of EDC and 0.15
mg of sulfo-NHS were added. After reaction overnight, a 1 M NaOH solution was added to change the
pH to 8 and then incubated for 30 minutes. Next, 25 pL of 50 mM glycine was added and stirred for 1
hour to quench the reaction. The solution was purified using GFC with the Superose TM 6 GL 10/300
column.
2.2.7 Synthesis of Polyacrylic Acid-PEG QD Gelatin Nanoparticles
Figure 2.2. Synthetic scheme for Polyacrylic Acid-PEG QD Gelatin Nanoparticles
Synthesis of Gelatin Nanoparticle. Gelatin nanoparticles were prepared from a modification of the two-
step desolvation method developed in (1). Gelatin type A (0.625 g) was added to 12.5 mL of DI water and
heated at 40'C until dissolution. The solution was then quickly removed from heat and 12.5 mL of
acetone was added to the solution at 6.0 mL/min while stirring at 300 rpm. After the acetone addition was
completed, the stirring was turned off. After exactly 1 min, the supernatant containing the low molecular
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weight gelatin fraction was removed. DI water (12.5 mL) was added to the remaining precipitate and
heated again to 40'C until dissolution. Half the solution was removed and the pH of the remaining half
was adjusted to 2.7 with a 1 M HCl solution. Under constant stirring at 600 rpm and 40'C, 20.75 mL of
acetone was added at 1.0 mL/min. Following addition of -17 mL of acetone, the solution appeared cloudy
white from the scattering by gelatin particles being formed. After the acetone addition was completed, 30
pL of 50% glutaraldehyde solution (grade I) diluted in 1 mL acetone was added to the gelatin solution at
0.05 mL/min to cross-link the particles. Subsequently, the solution was kept at 40'C and 600 rpm stir rate
for 7.5 hours. The acetone was then rotavapped off slowly to a final volume of 5-6 mL. The remaining
solution was filtered through a 0.2 pm syringe filter. A 1 M glycine solution (0.2 mL) was added and the
solution was stored overnight at 4'C. Instead of centrifugation to purify the nanoparticles, we used GFC
to prevent aggregation and an increase in size. A 1 mL solution of the gelatin particles was injected into a
SuperoseTM 6 GL 10/300 column (GE Healthcare, Piscataway, NJ) with 1x PBS as the mobile phase. The
peak eluting at the void volume was collected with 0.5 mL fractions. This was repeated once more and the
first concentrated fractions from both GFC runs were combined. This 1 mL solution was then taken to the
next step for QD conjugation and PEGylation.
Synthesis of Polyacrylic Acid-PEG QD Gelatin Nanoparticles. The 1 mL gelatin nanoparticle solution
was combined with 20 pL of 8 uM Qdot@ 565 ITKTM amino (PEG) QDs, and the solution was stirred at
130 rpm for 30 minutes. Afterwards, the pH was changed to 5 and then immediately adjusted to pH 6.
Stirring continued for 30 minutes. EDC (0.4 mg, 2.1 ptmol) and sulfo-NHS (0.4 mg, 1.9 ptmol) was
dissolved in 50 ptL of DI water and then added to the gelatin nanoparticle/QD mixture. The reaction
proceeded for 3 hours. Afterwards, a solution of mPEG amine 5 kDa (20 mg, -4 ptmol) dissolved in 50
piL of DI water was added to the gelatin/QD solution. Then an additional solution of EDC (0.4 mg) and
sulfo-NHS (0.4 mg) dissolved in 50 pL of DI water was added. After two hours, the pH was adjusted to 8
and stirring continued for 1 hour. A 1 M glycine solution (50 ptL) was added to quench the reaction. After
30 minutes, the resulting mixture was filtered through a 0.2 ptm syringe filter and then purified using GFC
with the SuperoseT M 6 column. The mobile phase used was 50 mM HEPES buffer at pH 7.5 for
subsequent in vitro characterization of the QD-Gelatin NPs or 1x PBS at pH 7.4 for subsequent in vivo
experiments. The peak eluting at the void volume was collected with 0.5 mL fractions and the first
concentrated fraction was used for further experiments.
2.2.8 Size Measurement
SEM. SEM samples were prepared by desalting the nanoparticle suspension two times using GFC with
DI water as the mobile phase. Then a 1:1 mixture of the resulting nanoparticle suspension in DI water and
acetone was drop-casted on a p-doped silicon substrate (University Wafer, South Boston, MA). The
sample was dried in air overnight, and then the surface was sputter coated with ~3 nm of gold-palladium.
Images were taken on a FEI/Philips XL30 field emission gun environmental scanning electron
microscope. Size analysis was performed by manually measuring 170 particles using ImageJ.
DLS. The measurements of nanoparticle hydrodynamic diameter were carried out on a DynaPro Titan
Dynamic Light Scatterer in pH ~7.5 50 mM HEPES buffer at 25'C. The result is the average of five
measurements of 10 acquisitions each.
2.2.9 Zeta Potential
The measurements of nanoparticle Q-potential were carried out on a Malvern Instruments
ZetaSizer ZS90 with the Universal Dip Cell at 25'C. For the measurements, 20 ptL of nanoparticle
suspension was dispersed in 800 pL of 50 mM HEPES buffer at either pH ~7.5 or ~6.0. The result is the
average of five measurements of 20 acquisitions each.
2.2.10 Fluorescence
Fluorescence spectroscopy was measured on a FluoroMax-3 (Horiba Jobin Yvon Inc., Edison,
NJ). For fluorescence microscopy of the size-changing NPs on a silicon substrate, a Nikon Eclipse
ME600 epifluorescence optical microscope equipped with a Nikon DXM 1200 digital camera was used.
2.3.11 Gel Filtration Chromatography (GFC)
The samples before and after cleaving with trypsin or collagenase were directly analyzed by GFC
with a Superose TM 6 GL 10/300 column (GE Healthcare, Piscataway, NJ) or a YMC-Pack Diol-200 (8 x
250 mm) on an Agilent 1100 series HPLC with an in-line degasser, autosampler, diode array detector, and
fluorescence detector (Roseville, CA). The injection volume was 45 pL and the mobile phase was 1x PBS
(pH 7.4) at a flow rate of 0.5 mL/min. The GFC chromatograms were detected by fluorescence detection
at 250 nm excitation wavelength and 565 nm emission wavelength or the entire emission spectrum from
500-650 nm was collected.
2.3.12 Fluorescence correlation spectroscopy (FCS)
FCS measurements were carried out on a custom-built inverted confocal microscopy setup
equipped with a Nikon Plan Apo VC (60x, 1.2 N.A.) water immersion objective. The 514 nm laser line
from an argon-krypton-ion laser (Innova 70C, Coherent Inc., Santa Clara, CA) at 6.2 ptW (measured at the
back aperture of the objective) was used for excitation. The emission was collected through the same
objective and spatially filtered by focusing through a 25 pim pinhole. Following a 550 nm long-pass filter,
the fluorescence was split using a 50-50 beamsplitter and recorded using avalanche photodiodes (SPCM-
AQR-13, Perkin Elmer, Shelton, CT). Cross-correlation was performed using a digital correlator
(ALV7004-FAST, ALV, Langen, Germany) and correlogram fitting was performed from lag time (T) 7.0
x 104 ms to 2.35 x 104 ms using the ALV software. Sample carriers were formed by sealing a silicone
perfusion chamber (PC8R-2.5, Grace Bio-Labs Inc., Bend, OR) over a 22 x 50 mm glass coverslip
(VWR, Pittsburgh, PA). The cover slip surface was pretreated with casein/PBS solution to prevent non-
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specific binding. HEPES (50 mM, pH 7.5) was used as the solvent. The QD suspension was diluted to
~0.2 mg/mL. The temperature during the measurement was -296'K. Five to ten measurements with
acquisition times of 60 seconds each were performed for each sample.
FCS Analysis. In our confocal setup, the axial dimension of the focal volume is significantly larger than
the lateral dimensions. Hence, it is sufficient to fit the cross-correlation function using the isotropic 2D
translational diffusion model,
g (r) - (1+r/rD) (3.1)
This allows us to obtain the correlation time for each measurement. Then we calculate the diffusion
coefficient using the equation:
D = w 2/4D (3.2)
The radius of the confocal detection volume (w>) was obtained using 0.10 ptm calibration standards (R100,
Thermo Scientific) and the QDs. Diffusion coefficients from repeated measurements were averaged.
Hydrodynamic radius was obtained from the mean diffusion coefficient using the Einstein-Stokes
equation:
D = kBT (3.3)
The value used for viscosity (ri) of water at 295.6'K was 9.4 x 10 4 Pa-s.
2.3 Results and Discussion
2.3.1 DHLA-PEG QD Peptide Silica Nanoparticles
Our first attempt to synthesize size-changing NPs was to conjugate DHLA-PEG QDs to the
surface of PEGylated SilicaQD NPs through MMP-2 cleavable peptides. The SilicaQD NPs were coated
with green-emitting non-cleavable QDs while the cleavable QDs were red-emitting. The two colors
allowed us to ascertain the cleavage through the separation of the two colors in our in vitro and in vivo
experiments. A disadvantage of this structure was that the cleavable peptide was buried in between the
red QDs and silica NPs. Moreover, both NPs were shrouded in a forest of PEG, which is known to reduce
the enzymatic degradation of peptides. An advantage is the simplicity of observing the cleavage in vivo
through separation of the red and green fluorescence in the tumor. The synthetic scheme initially involves
conjugation of a peptide linker with a polyhistidine tag at the N-terminal, a cysteine at the C-terminal, and
an MMP-2 cleavable sequence in between. The thiols on the peptides' cysteines were conjugated to the
amino-PEGs activated with sulfo-SMCC on the surface of the SilicaQD NPs. DHLA-PEG QDs were then
introduced and they self-assembled onto the SilicaQD NP surface due to the strong binding of
polyhistidine onto the surface of DHLA-PEG QDs. The solution was then centrifuged three times with
the supernatant containing the free QDs removed and replaced with fresh buffer solution each time. The
resulting solution was only weakly fluorescent. The QDs experienced a large drop in quantum yield
because of the dilute QD solution and low concentration of free DHLA-PEG ligands after the
centrifugation process. Low concentration of free ligands and low QD concentration speeds up the
desorption of DHLA-PEG ligands from the QD surface, increasing surface trap sites and particle
aggregation. One can add back free DHLA-ligands to mitigate this effect. The cleavable construct was
analyzed with GFC using fluorescence detection before and after incubation with collagenase and trypsin
(Figure 2.3). The chromatograms obtained before and after incubation with proteases did not show any
significant differences. The problems associated with this construct are the low fluorescence intensity and
possibly difficulty with cleaving due to the poorly accessible cleavable peptide.
650
600
550
500
-650
-C
4-J
c 6 00
550CC
0
E 500
650
600
550
5000 5 10 15
Time (min)
Figure 2.3. Gel-Filtration Chromatograms of DHLA-PEG QD Peptide Silica NPs before cleaving (A) and
after cleaving with trypsin (B) and with collagenase (C).
2.3.2 DHLA-PEG QD Gelatin Nanoparticles
We next attempted to construct our size-changing NP to be more sensitive to cleaving. Besides
using only peptide linker(s) between the 1 0-nm small QDs and 100-nm large NPs, another strategy is to
design the nanoparticle such that cleavage of each peptide can reduce the steric hindrance for the cleavage
of the remaining uncleaved peptides. For example, cleavage of peptides can compromise the PEG fortress
on the large NPs' surface or debulk the large NPs, initiating a cascade effect that makes it easier for
proteases to access and cleave the rest of the peptides. The more peptides that are critical to maintaining
the PEG on the large NPs' surface and/or the structure of the large NPs themselves, the more sensitive the
NPs will be to the proteases. Thus the large NPs can be synthesized to be well PEGylated to repel
adsorption by serum proteins (avoid opsonization and clearance by RES) but at the same time be highly
sensitive toward proteases. We will refer to this enhancement as gain. One scheme of synthesizing such a
structure is to conjugate PEG onto the surface of the large NP through a cleavable peptide such that
cleavage of peptide also removes a PEG molecule and reduces the PEGylation on the NP surface, making
it easier to cleave off additional PEG molecules and small NPs. Such a structure can yield modest gain
but synthesis may be expensive and tedious. A substantial amount of cleavable peptide needs to be
conjugated to relatively large PEG (> 2 kDa) and then purified with HPLC. Another possible structure is
to synthesize a large 100-nm NP that is composed entirely of cleavable peptides and with PEG either
incorporated in the particle core and/or the particle surface. Such a structure would yield very high gain;
once the cleavage occurs on the surface, the structural integrity of the NP becomes compromised. The
protease can penetrate into the NP and cleave from the inside outward, avoiding the thick outer PEG layer.
To our knowledge, synthesis of such a NP that also meets our other requirements such as size has not
been reported to date. However, instead of using cleavable peptides, gelatin, which is very sensitive to
cleavage by MMP-2 and MMP-9, have been made into NPs and explored as a possible nanotherapeutic
material due to its nontoxic and low immunogenic properties. In addition, gelatin is low cost, abundant,
and already used as a blood substitute and common additive in pharmaceuticals. These qualities make
gelatin highly favorable as the core material for our large NP.
We first attempted to encapsulate the DHLA-QDs into the core of gelatin NPs. The gelatin NPs
were synthesized using a method known as two-step desolvation. This method first dissolves gelatin in DI
water and then adds a non-solvent (acetone in our case) of gelatin that is miscible with water such that the
gelatin precipitates out of solution in a controlled fashion. In the first desolvation step, acetone is added
into the gelatin solution causing the high molecular weight (MW) gelatin to precipitate and collect onto
the bottom of the reaction vessel. The low MW gelatin is removed because this fraction is known to cause
particle instability if it is incorporated into the final gelatin NP. The high MW fraction is then redissolved
in water and the pH adjusted (typically to -2.7) such that it is far from the gelatin's isoelectric point.
During the second desolvation step, the addition of acetone (non-solvent) causes the gelatin to phase
separate from solution again. But this time, the gelatin has a higher charge (due to the large difference in
pH from the isoelectric point) and thus higher electrostatic repulsion from each other. Instead of
precipitating together all out of solution to the bottom of the reaction vessel, the gelatin forms small
clumps or nanoparticles instead because of their electrostatic repulsion. afterward, a solution of
glutaraldehyde (grade X) is added to cross-link the gelatin NPs so that they are stable after transferring
them back into water. After reaction for several hours (varied from 2 to 10), the gelatin NPs are purified
using GFC.
By adding a solution of DHLA-PEG QDs into the gelatin solution before the second desolvation
step, we were able to encapsulate the DHLA-PEG QDs into the gelatin NPs during the NP formation
process. Because the DHLA-PEG QDs are relatively "sticky" to proteins (Figure 2.8), these QDs bound
to the gelatin (Figure 2.7) and were incorporated with high efficiency. Dynamic light scattering (DLS)
measurements of these particles showed a hydrodynamic diameter of 96.6 nm (Figure 2.4c). The QD-
Gelatin NPs preserved the fluorescence spectrum of the QDs that they were synthesized from (Figure
2.4b). The absorption spectrum was dominated from scattering by the large large gelatin NPs (Figure
2.4d). Scanning electron microscopy (SEM) confirmed the particles were not aggregated and relatively
monodisperse.
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Figure 2.4 Physical Characterization of DHLA-PEG QD Gelatin NPs. (A) Gel-filtration chromatogram,
(B) fluorescence spectrum, (C) dynamic light scattering, and (D) absorption (scattering) spectrum
Centrifugation, scattering, and GFC were used to determine the size change of the NPs.
Incubation of these NPs with trypsin followed by centrifugation of the particles for 5 minutes at 3 krpm
indicated a size change had occurred (Figure 2.6). However, GFC analysis of the sample after cleaving
with collagenase showed the cleaved QDs had broad size distribution. GFC analysis of only DHLA-PEG
QDs incubated with gelatin and collagenase showed a similar chromatogram, suggesting the cleaved
gelatin fragments can bind to the surface of the DHLA-PEG QDs and result in large sized structures
(Figure 2.7).
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Figure 2.5. SEM of DHLA-PEG QD Gelatin NPs
Figure 2.6. Images of DHLA-PEG QD Gelatin NP solution after centrifugation and before (left) or after
(right) incubation with trypsin.
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Figure 2.7. GFC chromatogram comparison of DHLA-PEG QD Gelatin NP after incubation with
collagenase and DHLA-PEG QD with Gelatin after incubation with collagenase.
2.3.3 Imidazole-PEG QD encapsulated Gelatin Nanoparticles
The synthesis of the imidazole PEG QD encapsulated Gelatin NPs was the same as the previously
discussed DHLA-PEG QD-Gelatin nanoparticles except the DHLA-PEG QDs were replaced with
imidazole-PEG QDs (PIA) (2), which are much less "sticky" to proteins. The immediate problem we
encountered with the PIA QDs was their instability at the low pH range usually used (~2.7) for the second
desolvation step during gelatin NP synthesis. The imidazoles on the water-solubilizing polymers are the
key linkages that bind the polymer onto the QDs' surface. At pH lower than the pKa of imidazole (-6),
the imidazoles become protonated and the polymer begins to dissociate from the QDs' surface, resulting
in loss of QD fluorescence and precipitation of the QDs. The QDs lost their fluorescence rapidly after
being introduced into the low pH gelatin solution. The second desolvation can also be performed at high
pH (~12), which the QDs are very stable in. However, because the PIA QDs are much less "sticky" (high
coverage of PEG) to the gelatin (Figure 2.8), most of the QDs were not incorporated into the gelatin NP.
2.3.4 Imidazole-PEG QD coated Gelatin Nanoparticles
Instead of encapsulating the "non-sticky" PIA QDs in the gelatin NP core, we conjugated the PIA
QDs to the surface of the gelatin nanoparticle. The gelatin NPs were first formed, purified using GFC,
conjugated to the PIA QDs, and then purified using GFC again. We conjugated amine-functionalized PIA
QDs to the carboxylic acid groups on the surface of the gelatin NP using EDC/sulfo-NHS coupling
chemistry.
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However, the amines which we expected to be available for conjugation were actually binding to
the surface of the QDs, greatly reducing their conjugation efficiency. The conjugation efficiency was very
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low resulting in only 1-5 QD per gelatin nanoparticles when -80 QDs were introduced per gelatin NP
(measured from ICP-OES of QDs and Mie Scattering of Gelatin NPs). Using fluorescence correlation
spectroscopy (FCS), we were able to measure the size of the cleaved QDs after incubation with
collagenase (Figure 2.9). The FCS measurement showed the cleaved QDs were 27.9 nm (Table 2.1),
almost three times bigger than the size of the individual QDs. We postulated the large size was due to
attachment of the cleaved QDs to the large glutaraldehyde network that is not cleavable by proteases. We
also attempted to observe the cleaving in vivo for these cleavable constructs using the HT-1080 tumor
model. However, due to the low fluorescence intensity, we had difficulty imaging these particles in the
tumor. These two problems brought about a necessity to experiment with other QD gelatin NP constructs.
Figure 2.9. FCS correlograms of Imidazole-PEG QD Gelatin NPs synthesized using grade X
glutaraldehyde before incubation with collagenase (A) with residuals (B) and after incubation with
collagenase (C) with residuals (D).
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Sample FCS (corr. time) DLS (nm) DLS/FCS
GelatinQD 18.19 137.2 7.5426
Gelatin QD After 3.769
Collagenase
QD 1.405 10.58 7.5302
SilicaQD 18.05 131.3 7.2742
Size after cleaving with collagenase by FCS: 27.9 nm
Table 2.1. Size of QDs, SilicaQDs, and Imidazole-PEG QD Gelatin NPs before and after cleaving with
collagenase,.
2.3.5 Polyacrylic Acid QD-Peptide-Gelatin Nanoparticles
Instead of imidazole-PEG QDs, we switched to Invitrogen Qdot@ 565 ITKTM amino (PEG) QDs
based on the polyacrylic acid (PAA) PEG polymer for water solubilization. The PAA QDs (emitting at
565 nm) exhibited a high quantum yield (~70%) and the amines were more readily available for
conjugation, thus resulting in brighter size-changing NPs. Conjugation of the PAA directly to the surface
of the gelatin NP using EDC/sulfo-NHS coupling chemistry will be discussed in detail in the next section.
Because we believed the QDs were still attached to the large cross-linked glutaraldehyde network after
cleaving, we attempted to conjugate the QDs to the surface of the gelatin NP through a cleavable peptide
linker. The protease may be able to cleave the peptide linker and free the QDs from the glutaraldehyde
network. In order to prevent the QD from conjugating directly to the gelatin NP surface, we tried to
saturate the surface of the QD with cleavable peptides first before conjugating to the surface of the gelatin
NP. The synthesis resulted in large amounts of aggregates, probably a result of interparticle cross-linked
structures. Because both the QDs and gelatin NPs are multivalent, the conjugation is inevitably
susceptible to interparticle cross-linking. One way to avoid interparticle cross-linking is to use a
monovalent nanoparticle for the 10-nm nanoparticles, but an efficient method of synthesizing monovalent
QDs has not yet been developed. Another strategy to avoid interparticle cross-linking is to use a large
excess of the QDs and add the gelatin NPs to the QDs slowly. However, in order to get high loading, the
gelatin NPs need to have high number of reactive sites on their surface, which increases the number of
QDs necessary to prevent interparticle cross-linking. Thus to obtain both high loading and prevent
interparticle cross-linking, we need a very large excess of QDs to the gelatin NPs. Such a synthesis
scheme is very wasteful and is not practical for scale-up. It is possible to salvage the free small
nanoparticles after each reaction and use them again for subsequent reactions. But this method leads to
possible problems with the quality of the small nanoparticles after each reaction cycle. A practical way to
carry out this reaction is to react with only a limited number of reactive sites on the surface of the large
nanoparticles so that the probability of interparticle cross-linking is minimized and a very large excess of
QDs is not necessary. We lowered the amount of conjugation reagent to minimize interparticle cross-
linking which appeared successful. But this construct still yielded cleaved QDs that were much larger
than individual QDs. The problem may be that the peptides did not fully saturate the QD surface. We
moved on to another scheme, but it should be noted that further increase of the QD loading will require
careful optimization of the conjugation efficiency while avoiding interparticle cross-linking.
2.3.6 Polyacrylic Acid-PEG QD Gelatin Nanoparticles
We conjugated the amines on the PAA QDs directly to the carboxylic acid groups on the gelatin
NP surface using EDC/sulfo-NHS chemistry. GFC analysis of this construct after incubation with
collagenase showed most of the QDs eluted at the void volume (Figure 2.10); this result suggests most of
the QDs were not fully cleaved but still linked to a larger structure. Because gelatin should be completely
degraded by collagenase, the most likely explanation for the broad distribution is the presence of long
glutaraldehyde cross-links that are still conjugated to the QDs. Several strategies to solve this issue that
we attempted were:
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Figure 2.10. Incubation of Polyacrylic Acid-PEG QD Gelatin NPs (grade X glutaraldehyde) with
collagenase for 4 hours (A) and 20 hours (B).
1. Conjugate QDs to gelatin NPs through a cleavable peptide as discussed in the previous
section (2.3.5). However, we experienced problems with interparticle cross-linking and did
not observe an improvement in the size of the QD after cleaving. More optimization may be
necessary to saturate the surface of the QD with peptide.
2. Coating the surface of the gelatin NP with a layer of gelatin. The gelatin layer allows
collagenase to cleave completely in between the gelatin NP and QDs, bypassing the
glutaraldehyde. The problem we observed was that coating the gelatin nanoparticle with
gelatin caused the size to increase substantially.
3. Another strategy was to cross-link the gelatin nanoparticle with many short cross-links
instead of a few large glutaraldehyde cross-links. Thus when the collagenase cleaves the
gelatin, the fragment(s) of gelatin still attached to the QD are too small to add to the size of
...... .......  ........... . ... . ...... ........... .............
the QD. The challenge with this strategy is that using short cross-links tend to result in
unstable gelatin NPs. A balance must be made such that the gelatin NPs is stable but yet falls
apart completely after incubation with the protease.
Out of the three options above, the third one was shown to be effective in minimizing the size of
the cleaved QDs to be the same as individual QDs. There are three major grades of glutaraldehyde (Figure
2.11, Table 2.2): grade I, grade II, and grade X (which does not have its grade specified). Grade I
glutaraldehyde is predominantly monomers and produced small cleaved QDs but produced the broadest
size distribution for the gelatin NP. Grade II and grade X appears nearly the same through absorption
spectroscopy, but they exhibit different size distributions of cleaved QDs. The pH used in the desolvation
step also has an influence on the size of the gelatin NP after cleaving. A pH of 3.0 yielded cleaved QDs
with a small size, whereas a pH of 3.3 yielded cleaved QDs that were mostly still aggregated (Figure
2.13). Initially we used grade II or a 50:50 mixture of grade I:grade II for cross-linking the gelatin
nanoparticle at pH 3.0 which produced the largest percentage of small cleaved QDs (Figure 2.12).
However, when we used MMP-2 to cleave the Gelatin-QD nanoparticles, the cleaving rate was extremely
slow such that it was nearly negligible after12 hours. Since the amount of MMP-2 used is much smaller
than collagenase due to its substantially higher cost, the sample needed to be much more sensitive in order
to be cleaved by the commercial MMP-2. We were able to achieve highly sensitive gelatin NPs by using
grade I glutaraldehyde for cross-linking the gelatin nanoparticle. Grade I glutaraldehyde needed longer
reaction times and double the amount previously applied to achieve gelatin particle stability. More
thorough characterization of this construct's size-changing properties in vitro and in vivo will be
discussed in the next chapter.
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Figure 2.11. UV absorption spectra of different grades of glutaraldehyde.
400
Abs 235 nm Abs 280 nm A235/A280
GI 0.105 0.994 0.105634
G2 0.997 0.097 10.27835
GX 0.997 0.147 6.782313
Table 2.2. Comparison of absorbance at 235 nm (polymer) and 280 nm (monomer) for different grades of
glutaraldehyde
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Figure 2.12. GFC chromatogram of Polyacrylic Acid-PEG QD Gelatin NPs (1:1 ratio of G1:G2
glutaraldehyde) with collagenase. (a) Gelatin QD before collagenase. (b) Gelatin QD after cleaving with
collagenase (blue) and QD (red) is given as reference.
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Figure 2.13. Comparison of size and size-changing properties of Polyacrylic Acid-PEG QD Gelatin NPs
synthesized with different grades of glutaraldehyde, pH, and reaction time. The pH used during synthesis
for all samples was at 3.0 except for those specified as 'high pH' in which pH 3.3 was used. The reaction
time used during synthesis for all samples was at 4 hours except for those specified as '-2x rxn time' in
which the reaction time was 7.5 hours.
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Chapter 3
In Vitro and In Vivo Characterization of Size-
Changing Nanoparticle
3.1 Introduction
Exploration of different size-changing NP constructs in the last chapter revealed that the most
effective structure consisted of a gelatin NP core cross-linked with grade I glutaraldehyde and conjugated
on the surface with polyacrylic acid-PEG QDs. This construct bested the others in terms of the size of the
cleaved QDs, the kinetics of cleaving, the NPs' fluorescence intensity, and the structure's overall
simplicity. In this chapter, we present further characterization of the in vitro and in vivo size-changing
properties of this construct, which will be referred to as quantum dot gelatin NP or QDGelNP.
3.2 Materials and Methods
Note: The experiments were performed in collaboration with Dr. Triantafyllos Stylianopoulos, Jian
Cui, and John Martin.
3.2.1 Materials
Hydrochloric acid fuming 37% TraceSelect, Nitric Acid >69.0% TraceSelect, and
Ethylenediaminetetraacetic Acid, Disodium Salt Dihydrate (EDTA) were purchased from Sigma-Aldrich.
HEPES, and lOx PBS Liquid Concentrate were purchased from EMD Chemicals Inc. (Gibbstown, NJ).
Calcium chloride, and glycine were obtained from Mallinckrodt Baker Inc. (Phillipsburg, NJ). ICP-OES
cadmium standard 2% HN0 3 1,000 mg/L was purchased from Perkin Elmer (Shelton, CT). GIBCO@
Certified Heat-Inactivated Fetal Bovine Serum was obtained from Invitrogen (Eugene, Oregon). BlockTM
Casein in PBS was purchased from Thermo Scientific (Rockford, IL). Reagent grade deionized water
used for ICP-OES experiments was purchased from Ricca Chemical Company (Arlington, Texas). Water
for all other experiments was obtained using a Barnstead NANOpure@ DIamond Life Science UV/UF
TOC water system (Thermo Fisher Scientific, Suwanee, GA). Active Human Recombinant MMP-2 was
purchased from EMD Chemicals Inc. (Gibbstown, NJ).
3.2.2. Gel Filtration Chromatography (GFC)
GFC was performed on the QDGelNPs before and after incubation with MMP-2 for various
lengths of time. Four samples of 0.1 mg QDGe1NP in 50 mM HEPES, 2 mM CaCl2 were incubated with
230 ng of MMP-2 for 0.25, 2.25, 5, or 12 hours at 37'C. At the end of the incubation time, EDTA
solution was added to give a final concentration of 20 mM EDTA to inhibit further MMP-2 degradation.
The samples before and after cleaving with MMP-2 were directly analyzed by GFC with a SuperoseTM 6
GL 10/300 column (GE Healthcare, Piscataway, NJ) on an Agilent 1100 series HPLC with an in-line
degasser, autosampler, diode array detector, and fluorescence detector (Roseville, CA). The injection
volume was 45 p.L and the mobile phase was 1x PBS (pH 7.4) at a flow rate of 0.5 mL/min. The GFC
chromatograms were detected by fluorescence detection at 250 nm excitation wavelength and 565 nm
emission wavelength, allowing us to measure only the elution profile of the QDs. Due to changes in the
QD fluorescence intensity over time and scattering effects, the chromatograms' integrated intensities from
13 to 38 min were normalized to unity. We then analyzed the percentage of QDs that were released over
time. The peak corresponding to the free QDs was integrated (from 18-38 min) and then corrected for
peak tailing from the peak at void volume. A simple peak tailing correction was done by assuming that
for a certain integrated area of the peak at void volume, a fixed percentage of that integrated area will be
added to the peak for free QDs. This fixed percentage (26.5%) was obtained using QDGelNP before
cleaving, which should elute completely at the void volume if not for peak tailing.
3.2.3 Fluorescence Correlation Spectroscopy (FCS)
FCS measurements were carried out on a custom-built inverted confocal microscopy setup
equipped with a Nikon Plan Apo VC (60x, 1.2 N.A.) water immersion objective. The 514 nm laser line
from an argon-krypton-ion laser (Innova 70C, Coherent Inc., Santa Clara, CA) at 6.2 ptW (measured at the
back aperture of the objective) was used for excitation. The emission was collected through the same
objective and spatially filtered by focusing through a 25 pm pinhole. Following a 550 nm long-pass filter,
the fluorescence was split using a 50-50 beamsplitter and recorded using avalanche photodiodes (SPCM-
AQR-13, Perkin Elmer, Shelton, CT). Cross-correlation was performed using a digital correlator
(ALV7004-FAST, ALV, Langen, Germany) and correlogram fitting was performed from lag time (r) 7.0
x 10-4ms to 2.35 x 104 ms using the ALV software. Sample carriers were formed by sealing a silicone
perfusion chamber (PC8R-2.5, Grace Bio-Labs Inc., Bend, OR) over a 22 x 50 mm glass coverslip
(VWR, Pittsburgh, PA). The cover slip surface was pretreated with casein/PBS solution to prevent non-
specific binding. HEPES (50 mM, pH 7.5) was used as the solvent. The QDGelNP suspension was
diluted to -0.2 mg/mL. The temperature during the measurement was -296'K. Five to ten measurements
with acquisition times of 60 seconds each were performed for each sample.
FCS Analysis. In our confocal setup, the axial dimension of the focal volume is significantly larger than
the lateral dimensions. Hence, it is sufficient to fit the cross-correlation function using the isotropic 2D
translational diffusion model,
g (T) - 1 (4.1)
Np (1+T/r'E)
This allows us to obtain the correlation time for each measurement. Then we calculate the diffusion
coefficient using the equation:
D =- (4.2)4
TD
The radius of the confocal detection volume (o) was obtained using 0.10 gm calibration standards (R100,
Thermo Scientific) and the QDs. Diffusion coefficients from repeated measurements were averaged.
Hydrodynamic radius was obtained from the mean diffusion coefficient using the Einstein-Stokes
equation:
D = kBT (43)
67Tr~l
The value used for viscosity (9) of water at 295.6'K was 9.4 x 10 - Pa-s.
3.2.4 ICP-OES
The concentration of QD in a QDGelNP sample was determined by measuring its Cd content and
then comparing it to the Cd content in a QD sample of known concentration. The QDGelNP and QD
standard solutions were first completely dissolved in aqua regia (HCl:HN0 3 = 3:1) solution, and then its
Cd content was determined using a Horiba Jobin Yvon Activa ICP-OES instrument. QDGelNP in
solution (300 pL) was heated to 130'C in a glass vial until the water has completely evaporated. Fresh
aqua regia solution (250 ptL) was added to the dried QDGelNP sample. The solution was covered with
parafilm and sonicated for 5 minutes. Afterwards the solution was heated overnight at 65'C. DI water
(1.75 mL) was added the next day using VWR@ LabmaxTM Bottle-Top Dispenser. Samples made from
cadmium ion calibration standards and known amount of QDs were prepared by the same method. These
solutions were prepared so that their Cd concentration would fall above and below the QDGelNP
sample's Cd concentration. The calibration was linear with an error of less than 2%. The ICP-OES
intensity was the average of five (30sec) exposures. A calibration curve for the amount of QD was created
using the QD standard solutions to give a value for the mole of Cd per mole of QD. This value was used
to determine the amount of QD in the QDGelNP solution.
3.2.5 X-ray Photoelectron Spectroscopy (XPS)
QDGelNPs with and without PEGylation were transferred to DI water by centrifugation at
10,000 rpm for 10 min and washed with DI water three times. The particles were then drop-casted on a p-
type silicon substrate (University Wafer, South Boston, MA) and dried overnight in vacuum. The samples
were characterized using a Kratos AXIS Ultra Imaging X-ray Photoelectron Spectrometer (Kratos
Analytical, Chestnut Ridge, NY) with a monochromatized Al Ka X-ray source. High resolution analysis
of the Cl s spectra was performed to determine the chemical composition from the hydrocarbon (C-C or
C-H at 285.0 mV), ether (C-O at 286.4 mV), carbonyl (C=O at 288.2 mV), and carboxyl (C=O at 289.1
mV) envelops. Deconvolution of the spectra determined the area under the peak for each chemical species
and thus their relative composition.
3.2.6. In Situ Zymography
The procedure developed in (1) was used. Cryostat section of an HT- 1080 tumor was air-dried for
10 min. DAPI was added to a 1% (w/v) low gelling temperature agarose in PBS to give a final
concentration of 1.0 ptg/mL. This solution was then combined with a 1.0 mg/mL solution of DQTM gelatin
(Invitrogen, Eugene, OR) in a 10:1 ratio. The combined mixture (40 pl) was put on top of the tumor
section and enclosed with a coverslip. After gelation of the agarose at 4'C, the gel and the tumor section
was incubated for 2 hours at room temperature. The cell nuclei stained with DAPI and unquenched FITC
from MMP digestion of DQTM gelatin were imaged on a confocal microscope. Fluorescence of FITC was
detected with excitation at 460-500 nm and emission at 512-542 nm. DAPI was detected with excitation
at 340-380 nm and emission at 425 nm.
3.2.7 Collagen Gel Diffusion
Collagen hydrogels were prepared by mixing the following components in order on ice: 141.75
ptL of 8.6 mg/ml rat tail collagen 1 (354249, BD Biosciences), 3.8 pL of 1 N sodium hydroxide, and 19.5
ptL of 0.17 M EDTA. The final concentration of collagen was 7.38 mg/ml and EDTA was 20 mM. After
vortexing, the gel was added to partially fill a microslide capillary tube (Vitrocom Inc. No. 2540, Mt.
Lakes, NJ), then incubated overnight at 37'C. QDGelNPs (0.1 mg) were incubated with 230 ng of
activated MMP-2 for 12 hours in 50 mM HEPES 2 mM CaCl2. At the end of 12 hours, EDTA was added
to give a final concentration of 20 mM. A 20 ptL mixture of the QDGelNPs either before or after
incubation with MMP-2 and SilicaQDs was added into the capillary tube and placed in contact with the
surface of the collagen gel. The concentration of the two particles and sensitivity of the avalanche
photodiodes (APD) were adjusted so that both particles gave similar signal intensities. The sample was
left in ~295 K for 12 hours and then imaged using a multiphoton laser scanning microscope. Image
analysis was performed using ImageJ. The concentration profile for the QDGelNPs after cleaving was
fitted to the following one-dimensional model to obtain the diffusion coefficient in the collagen gel (2):
C(x, t) oc erfc( ) (4.4)2 Defft
where erfc is the complementary error function. The nonlinear curve fitting was performed using
fminsearch in Matlab@. The diffusion coefficient ratio (D/D) was compared to reported values in (3) and
(4). In (4), D/DO was found to be -0.35 for an 11.2 nm QD in 9.37 mg/mL collagen gel. In (3), a value of
-0.95 for D/DO was obtained for a ~10 nm particle in 2.4 mg/mL collagen gel. Values for D/D, obtained
for higher concentrations of collagen gel from (3) were not used because these concentrations were
prepared by centrifuging low-concentration gels and these results did not match gels prepared directly
from high-concentration solutions. By simple linear interpolation of these two values, we obtained a D/DO
for ~10 nm NP in 7.38 mg/mL collagen of 0.52.
Figure 3.1. Experimental setup for intratumoral injection
3.2.8 Intravital Multiphoton Microscopy
All animal procedures were done following the guidelines of the Public Health Service Policy on
Humane Care of Laboratory Animals and approved by the Institutional Animal Care and Use Committee
of the Massachusetts General Hospital. Human fibrosarcoma HT-1080 cells were implanted in the dorsal
skin of severe combined immunodeficient (SCID) mice for in vivo imaging (5, 6). When tumors reached 5
mm in diameter, we injected a 1 pL mixture of QDGelNPs and SilicaQDs (~ .05 p1/min) into the tumor
at constant pressure using a glass micropipette connected to a syringe filled with silicone oil (Figure 3.1).
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Images were obtained with a custom-built multiphoton microscope using a Ti:Sapphire laser (Mai-Tai
Broadband; Spectra-Physics, Mountain View, CA) at 900 inm, a 20x(0.5NA; Olympus) water-immersion
objective, and photon-counting photomultiplier tubes (H7421-40; Hamamatsu). Detection of QDGelNPs
was performed via a 530DF100 emission filter and SilicaQDs via a 610DF75 emission filter. Collagen
fibers were imaged with second-harmonic generation (2, 7, 8) via a 450DF100 emission filter. The laser
power was set to 500 mW. Three dimensional image stacks containing 21 images of 5 pm thickness were
obtained wherever fluorescence intensity from the injected particles was detected. A maximum intensity
z-projection of each colored stack generated a 2D image. Images of consecutive adjacent regions in the x
and y directions were combined into a montage, generating a single image of the entire injection site.
The intensity profiles along the dotted lines in Figure 3.14 were extracted using ImageJ and then
normalized such that the backgrounds (a "dark" region from all three time-lapse images) had the same
intensity. The background was subtracted and the resulting profiles was fitted (Figure 3.15) to the model
for diffusing substance initially distributed uniformly through a sphere of radius a (9) to obtain the
diffusion coefficient:
C(r, t) = CO erf + erf a -r [exp t - (a r>2 t (a+r)l] (4.5)2 0 I2 VD- -_~ r [ep 4Dt J 'I 4Dt J
where C0 is the initial concentration in the sphere. It should be noted that the diffusion coefficient
obtained in collagen gel was obtained at -295 K while the in vivo experiment was measured at the slightly
higher body temperature of -3 10 K.
3.2.9 Blood half-life
The procedure in (10) was used. Nanoparticle circulation times were measured in non-tumor
bearing female SCID mice. Each mouse was anesthetized with a ketamine/xylazene solution before
intravenous infusion of nanoparticles by retro-orbital injection. For each time point, starting 1 min before
the injection of particles, we collected 13 pL of blood via tail-vein nick and mixed this sample with 3 IL
50 mM EDTA in a plastic 96-well plate. To measure particle concentrations in the blood over time, we
imaged in these samples using multiphoton microscopy to measure average intensities. To quantify the
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clearance half-life, we fit a biexponential curve, taking into account tissue absorption and plasma
clearance, to the data from each mouse.
3.3 Results
The multistage quantum dot gelatin nanoparticles (QDGelNPs) are composed of a gelatin core
with amino-PEG QDs conjugated to the surface using EDC/sulfo-NHS coupling chemistry. Another layer
of 5 kDa PEG is conjugated to the surface of the gelatin nanoparticles to confer long blood circulation
time. X-ray photoelectron spectroscopy (XPS) was used to determine the presence of PEG chains on the
QDGelNPs surface (Figure 3.4). Dynamic light scattering (DLS) of the QDGelNPs before and after
PEGylation (but before purification) indicate an increase in diameter from 78.3 ± 0.2 nm to 93.7 ± 0.5
nm. DLS of the final structure after purification and size selection using GFC revealed a single particle
distribution with a hydrodynamic diameter of 97.9 ± 2.1 nm and a polydispersity of 41.2% (Figure 3.3).
This value agreed well with the average diameter of 99 ± 1 nm estimated from scanning electron
microscopy (SEM) (Figure 3.2c and 3.2d). Inductively coupled plasma optical emission spectroscopy
(ICP-OES) determined a concentration of 15 pmol of QDs per mg of QDGelNPs. The QDGelNPs showed
excellent colloidal stability; their diameter by DLS remained nearly unchanged while in storage at ~4'C
over 48 days - from 95.7 ± 4.1 nm on day 1 to 101.1 ± 2.5 nm on day 48 (Figure 3.2b, Table 3.2).
We designed both the initial 100-nm NPs and the released 10-nm NPs to have a neutral surface
charge, ensuring the difference in transport before and after cleaving is only a result of size change. In
addition, previous report suggested neutral particles are optimal for diffusion in the interstitial matrix (4).
The ( potential of the ~100 nm QDGelNPs at pH 7.5 was -6.29 ± 0.22 mV and at pH 6 was -5.00 ± 0.12
mV. The ( potential of the ~10 nm QDs used for the second stage NP was -5.13 ± 0.16 mV at pH 7.5 and
-4.36 ± 0.17 mV at pH 6 (Figure 3.3c and 3.3d, Table 3.1). These results confirm the charge neutrality of
both particles in the pH range found in normal tissues and solid tumors.
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Figure 3.2. QDGelNP physical and in vitro characterization. (A) Epifluorescence image of QDGelNPs on
a silicon substrate at 1 00x magnification. Scale bar 5 pm. (B) DLS distribution of QDGeINP on day 1 and
day 48 after synthesis and storage at 4'C. (C) Histogram of QDGelNPs' size distribution from image
analysis of SEM image. (D) SEM image of QDGeINPs at 15,OOOX magnification. Scale bar 1 im. (Inset,
bottom) SEM image of individual QDGeINP at 35,OOOX magnification. Scale bar 100 nm. (D)
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Figure 3.3. DLS size and zeta potential distributions of QDGelNPs and QDs. DLS mass percent particle
size distributions of QDGelNPs (A) and QD (B). Zeta Potential distributions of QDGelNPs (C) and QDs
(D).
QDGeINP QD
Diameter (M ± SEM, nm) 97.9 ± 2.1 12.5 ± 0.1
Percent Polydispersity 41.2% 31.0%
Zeta Potential at pH -7.5 (M ± SEM, nm) 6.29 ± 0.22 5.13 ± 0.16
Zeta Potential at pH -6.0 (M ± SEM, nm) 7.70 ± 0.16 4.36 ± 0.17
Table 3.1. Mean value and S.E.M. of five DLS size
QDs
or zeta potential measurements for QDGelNPs and
DLS
QD
12.6 nm
Diameter (nm)
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Figure. 3.4. High resolution XPS spectra of C1s region for QDGelNPs before PEGylation (A) and after
PEGylated (B). Peak deconvolution of the spectra show the intensities for the C-H (hydrocarbon), C-O
(ether), C=O (carbonyl), and C(=O)-O (carboxy) peaks at 285.0, 286.4, 288.2, and 289.1 eV binding
energies, respectively. The greater percent area for the C-O peak after PEGylation (B) is attributed to the
additional C-O bonds in the PEG surface coating.
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Figure 3.5. DLS distribution of QDGelNP on day 1 and day 48 after synthesis and storage at 4*C.
Day 1 Day 48
Diameter (M ± SEM, nm) 95.7 ± 4.1 101.1 ± 2.5
Percent Polydispersity (M ± SEM, %) 53.4 ± 3.8 50.9 ± 2.4
Table 3.2. Mean value and S.E.M. of five DLS size measurements for QDGelNP on day 1 and day 48
after synthesis and storage at 4'C.
In Vitro Size Change
We next investigated the ability of MMP-2 to change the size of QDGelNPs in vitro using GFC.
GFC chromatograms using fluorescence detection (ex: 250 nm, em: 565 nm) were obtained from
incubation of 0.1 mg of QDGelNPs with 230 ng (0.16 ptM) of MMP-2 at 37'C (Figure 3.6b). A previous
report has estimated the extracellular concentration of MMP-2 in HT-1080 (human fibrosarcoma)
xenograft tumor tissue in vivo to be -1 mM (11), significantly higher than the concentration used in our in
vitro experiment. The QDGelNPs initially eluted at the GFC column's void volume but after incubation
with MMP-2 for various times up to 12 hours, the peak shifted to a longer elution time corresponding to
the smaller size of individual QDs, whereas incubation with 50% fetal bovine serum (FBS) showed no
such shift (Figure 3.7). We assessed that 50% of the QDs were released in -1.5 hours and the percent of
freed QDs saturated at ~90% (Figure 3.8a), regardless of longer incubation times or addition of more
MMP-2. We repeated this experiment with the incubation time kept constant at 12 hours but the amount
of MMP-2 was varied (Figure 3.8b). Under this condition, only -25 ng of MMP-2 was necessary to
release 50% of the QDs. These results demonstrated the MMP-2 triggered size change occurred in an
efficient and nearly complete manner.
We then verified that the released QDs diffuse optimally in the interstitial matrix, that residual
gelatin/glutaraldehyde on their surface, imparted by cleavage of the gelatin NPs, do not lead to extraneous
binding interactions or significant size increase. To investigate this possibility, we used FCS to directly
measure the hydrodynamic diameter/diffusion coefficient of the QDs before and after cleaving the gelatin
core (Figure 3.9, Table 3.3). The hydrodynamic diameter by FCS before cleaving was 81.1 ± 2.3 nm (D
5.6 ± 0.2 x 10-8 cm2 s-'), which is consistent with the DLS measurement of 90.9 ± 1.3 nm for this batch.
After MMP-2 digestion, the hydrodynamic diameter decreased to 9.7 ± 0.3 nm (D = 4.7 ± 0.2 x 10-7 cm2
s-'), which is the size of individual QDs, indicating the size increase of the released QDs from
gelatin/glutaraldehyde fragments was negligible.
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Figure 3.6. QDGelNPs change their size in response to MMP-2. (A) Schematic of 100 nm QDGelNPs
changing size to 10 nm QD NPs by cleaving away the gelatin scaffold with MMP-2, a protease highly
expressed in tumor tissue. (B) GFC chromatograms of QDGelNPs at various times after incubation with
MMP-2. Fluorescence signal at 565 nm is collected. (Inset) Fluorescence spectrum of the peak at void
volume for 2.2 hours cleaving time shows that the signal originates from QDs on the QDGelNPs.
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Figure 3.7. GFC chromatograms of QDGelNPs and QDGelNPs incubated with 50% FBS for 13 hours
indicate no peak corresponding to release of individual QDs. Chromatograms of QDs and QDs incubated
with 95% FBS are provided as reference.
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Figure 3.8. Kinetics of MMP-2 induced QD release from QDGelNPs (A) QD-release curve from
incubation of 0.1 mg (0.16 pM) of QDGelNPs with 230 ng of MMP-2 (B) QD release from incubation of
0.n1 mg of QDGelNPs for 12 hours with varying amounts of MMP-2.
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Figure 3.9. FCS cross-correlograms of QDGelNPs before (A) and after (B) incubation with MMP-2.
Summary of FCS Results
Diameter by FCS before MMP-2 (M ± SEM, nm)
Diameter by FCS after MMP-2 (M ± SEM, nm)
Diameter by DLS before MMP-2 (M SEM, nm)
Percent Polydispersity by DLS
81.1 ±2.3
9.7 ± 0.3
90.9 ±1.3
43.4%
Table 3.3. Mean value and S.E.M. of five FCS measurements for QDGelNPs before and after incubation
with MMP-2. Hydrodynamic diameter obtained from DLS for QDGelNPs before incubation with MMP-2
is also provided.
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We next evaluated whether the size change observed in GFC and FCS enhances diffusive
transport in dense collagen environments resembling those in solid tumors. To simulate the interstitial
matrix of a solid tumor, we prepared a collagen gel in a capillary tube at 0.74% (7.4 mg/mL)
concentration, similar to the reported estimate of 9.0 ± 2.5 mg/(mL interstitial matrix) for interstitial
collagen in both human colon adenocarcinoma (LS 174T) and murine mammary carcinoma (MCalV)
implanted in mouse dorsal chambers (3, 12). The collagen gel penetration of the QDGelNPs before and
after cleaving with MMP-2 was compared to a non-cleavable, PEGylated, and QD-coated silica
nanoparticles (10) control (Diam. = 105.6 ± 0.8 nm, ( potential at pH 7.5 = -3.9 ± 0.2 mV) - designed to
behave like QDGelNPs before cleaving. A mixture of SilicaQDs and QDGelNPs (before or after
cleaving) were placed in contact with the gel and incubated for 12 hours. Infiltration of both particles into
the collagen was determined using multiphoton microscopy with simultaneous second-harmonic
generation (SHG) imaging of fibrillar collagen (Figure 3.10). The SilicaQDs and QDGelNPs before
cleaving both had negligible penetration and were excluded from the collagen matrix (Figure 3. 10a and
3.1 Ob). However, after cleavage of QDGelNPs with MMP-2, the freed QDs were able to penetrate over a
millimeter into the gel (Figure 3.1 Of and 3.1 Oh). By fitting the concentration profile of the cleaved
QDGelNPs to a one-dimensional diffusion model (2, 9), we obtained a diffusion coefficient of 2.3 x 10-'
2 I
cm s , the same diffusion coefficient obtained for individual QDs in the collagen gel before conjugation
to the gelatin NP. The resulting diffusion coefficient ratio (D/D,, where D, is diffusion coefficient of
freed QDs in solution obtained by FCS) in the collagen matrix is 0.49. This value agrees well with the
expected value for D/D, of ~0.52 derived from previous reports (see Methods for Collagen Gel) (3, 4).
This result indicates that the diffusion coefficient of released QDs in dense collagen increases to that of
~10 nm particles and any residual gelatin/glutaraldehyde fragments remaining on the surface do not
impede their diffusion.
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Figure 3.10. Diffusion of SilicaQDs and QDGelNPs (before and after MMP-2 cleavage) in a collagen
gel. (AB) Fluorescence images of SilicaQDs (A) and QDGelNPs before MMP-2 cleavage (B) penetrating
into the collagen gel. (C) Second-harmonic generation (SHG) signal shows the corresponding location of
the collagen matrix. Scale bars, 125 m. (D) Normalized intensity profile of SilicaQDs and QDGeNPs in
collagen gel. (E, F) Fluorescence images of SilicaQDs (E) and QDGelNPs after MMP-2 cleavage (F)
penetrating into the collagen gel. (G) SHG signal shows the corresponding location of the collagen
matrix. Scale bars 125 jim. (H) Normalized intensity profile of SilicaQDs and QDGelNPs after MMP-2
cleavage in collagen gel. Black line displays theoretical intensity profile for particles with diffusion
coefficient of 2.3 x 10- cm2 s-.
102
..........
1000
Distance (pm)
Figure 3.11. Diffusion of SilicaQDs and QDs in a collagen gel. (A,B) Fluorescence images of SilicaQDs
(A) and QDs (B) penetrating into the collagen gel. (C) Second-harmonic generation (SHG) signal shows
the corresponding location of the collagen matrix. Scale bars, 125 pm. (D) Normalized intensity profile of
SilicaQDs and QDs in collagen gel.
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Figure 3.12. Particle distribution and second-harmonic generation (SHG) from collagen fibrils at
collagen-solution interface in collagen gel experiment (Figure 3.10). (A) The intensity profile of
SilicaQDs and QDGelNPs before cleavage in comparison with SHG indicates the exclusion of both sets
of particles from the collagen matrix. (B) Intensity profile of SilicaQDs and QDGelNPs after cleavage in
comparison with SHG shows penetration of QDGelNPs into the collagen but exclusion of SilicaQDs.
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In Vivo Characterizations
To test whether tumor secreted MMP-2 can change the size of QDGelNPs in vivo, we
intratumorally co-injected QDGelNPs and SilicaQDs in the HT-1080 tumor implanted in the dorsal skin-
fold window chamber of SCID mice. The HT-1080 tumor model was selected because of its reported high
MMP-2 activity, which we confirmed by in situ gelatin zymography on a tumor tissue section (Figure
3.12). Multiphoton microscopy revealed a marked increase in QDGelNPs penetration into surrounding
tumor tissue as compared with the non-cleavable SilicaQDs control, confirming a substantial
enhancement in interstitial transport associated with size change (Figure 3.13 and 3.14). At 6 hours post-
injection, the QDGelNPs had penetrated up to ~300 ptm from the injection site while the SilicaQDs
control exhibited little or no dissemination from its initial location. We fitted the concentration profile to a
model for substances diffusing from a spherical source to obtain an effective diffusion coefficient of -2.2
x 10-8 cm 2 s- inside the tumor (Figure 3.15). This value is -10% the diffusion coefficient obtained in the
collagen gel, which can be explained by the increased time needed to cleave the particles, the geometric
tortuosity of the interstitial space induced by cellular obstacles (6), and the possibly higher collagen
concentration in the HT-1080 tumor than in the gel we prepared.
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Figure 3.13. In situ zymography of gelatinase enzymatic activity in HT-1080 and 4T1 tumor models.
DAPI stains for location of nuclei in 4T1 (A) and HT-1080 (B) tumors. Signal from cleaved DQTM gelatin
reveals location of gelatinase activity in 4T1 (C) and HT-1080 (D) tumors. The high DQ TM gelatin signal
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Figure 3.14. In vivo images of QDGelNPs and SilicaQDs after intratumoral co-injection into the HT-
1080 tumor. QDGelNPs imaged 1 hour (A), 3 hours (B), and 6 hours (C) post-injection. SilicaQDs
imaged 1 hour (A), 3 hours (B), and 6 hours (C) injection. Scale bar 100 pim.
106
............. 
.... . ....
6 hours1 hour
3 hours
QDGeINPs
SilicaQDs
200
150
100
-s -o- 5
Figure 3.15. Heat map of QDGe1NP and SilicaQD distributions after intratumoral co-injection into HT-
1080 tumor. QDGelNP heat maps after 1 hour (A), 3 hours (B), and 6 hours (C). SilicaQD heat maps after
1 hour (A), 3 hours (B), and 6 hours (C). Scale bars 100 pm.
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Figure 3.16. Radial intensity profiles of QDGeLNP (along dotted line in Figure 3.14) after intratumoral
injection in HT-1080 tumor and the corresponding fits from model of diffusing substance from a spherical
source.
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Figure 3.17. Blood concentration of QDGelNPs and SilicaQDs as a function of time post-injection. Error
bars indicate standard error of three animals.
We next determined the QDGelNPs' blood half-life (t1/2 0) to show that the QDGelNPs are not
rapidly removed from circulation by the reticuloendothelial system (RES). We systemically administered
to non-tumor bearing mice a mixture of the QDGelNPs and SilicaQDs by retro-orbital injection and
measured the decrease in fluorescence from both particles in the blood over time. The SilicaQDs
exhibited a blood half-life of 12.9 ± 2.4 hours while the QDGelNPs had a half-life of 22.0 ± 3.4 hours
(Figure 3.16). The difference in the half-lives may be due to variations in the QDGelNPs' surface
chemistry that make it less immunogenic compared to SilicaQDs. These results established that
QDGelNPs possess both the long circulation half-life and large 100-nm size necessary for preferential
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extravasation from the leaky regions of the tumor vasculature as well as the deep interstitial penetration of
a 10-nm particle required for delivery to the tumor's poorly accessible regions.
Our FBS incubation experiment suggested the QDGelNPs are stable in serum conditions but
additional studies will be needed to verify that the QDGelNPs are not degraded in the blood by circulating
MMPs (13) and other proteases. Circulating MMPs, however, have been reported to be inhibited by
serum proteins such as a2-macroglobulin that entrap the MMPs (14, 15). The degree of PEGylation on
the surface of the QDGelNPs may need to be optimized such that there is minimal cleaving and
opsonization in the blood while achieving the desired release rate in tumor tissue. However, MMP levels
may vary in different tumor types/individuals causing inconsistent behavior. A strength of our method is
the potential for customized delivery of nanoparticles using genomic and molecular data to achieve
optimal delivery for a particular patient. For example, high levels of tumor-specific urinary MMPs
measured noninvasively in an individual can be indicative of high levels of the MMPs in plasma and
tumor tissues (16). This information can help us customize the QDGelNPs for lower sensitivity to
proteases (e.g., by increasing the particles' cross-linking) to minimize degradation in the blood while
maintaining the same desired release rate in the tumor.
3.4 Discussion
Multistage nanoparticle systems provide additional tunability in the spatial control of delivery to
solid tumors. Due to the multiple physiological barriers that a therapeutic agent must encounter, a
multistage nanoparticle system can enhance penetration by changing its size, charge, shape, flexibility
and/or surface coating to suit the transport across each barrier. We can extend the utility of this approach
by incorporating additional stages into the QDGelNPs to guide its delivery into tumor cells or even
subcellular compartment(s). Such an approach may not only improve the efficacy of current anticancer
drugs but also make available drugs that have previously been abandoned due to delivery problems. As
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interest in increasingly sophisticated delivery systems grows, we face a corresponding challenge to
synthesize nanostructures of increasing complexity. Innovative schemes will be necessary to assemble
nanocomponents in complex configurations that keep the synthesis simple yet functional so that
production can be scalable and cost-effective.
We have provided a proof-of-principle demonstration that a size-changing nanoparticle can
facilitate delivery into the dense collagen matrix of a tumor. In future work, we plan to further
characterize the particle's biodistribution, pharmacokinetics, and tumor-associated transport properties.
Ultimately, the QDs will be replaced with a 10-nm nanocarrier of cancer therapeutics and its antitumor
efficacy and survival benefits will be compared to that of conventional drugs and other nanoparticle-based
treatments. The loading capacity per 10-nm nanocarrier is limited. Therefore, not only the penetration
depth but also sufficient quantity of nanoparticles needs to be delivered.
The size of the nanocarrier we selected for the first and second stage, 100 nm and 10 nm,
respectively, may not be the optimal size for transport across each of the physiological barriers the
nanoparticles were intended for. The second-stage 10-nm nanocarriers, designed to diffuse in the
interstitial space, would probably diffuse even better if they were smaller (e.g., 3-4 nm). The 100-nm
nanoparticles used for the first-stage carrier were motivated by current FDA-approved nanomedicine such
as the -100 nm PEGylated liposomal nanotherapeutic Doxil@, which exhibited the EPR effect but does
not penetrate well into the interstitial space. However, 100 nm may not be the optimal size for the EPR
effect but may have been chosen because synthesizing smaller PEGylated liposomes, such as 10 nm, was
not possible. In fact, 6-nm drug-polymer conjugate unimolecular micelles have already been shown to
exhibit prolonged circulation time and reduced adverse effects associated with administration of the free
drug (17). A 100-nm nanocarrier for the first stage may show even higher reduced adverse effects but
more work is still needed to study the effects of nanoparticle size on accumulation in normal tissues such
as the bone marrow and heart. 10-nm NPs will likely accumulate in the liver more rapidly due to the
liver's 100-nm fenestrations; however, the liver is the endpoint for metabolism of the NPs anyways and is
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a relatively robust organ. Thus, if 100-nm and 10-nm NPs have the same circulation half-life, the 1 0-nm
NPs may not be at a disadvantage even if the 10-nm NPs have higher accumulation in the liver. In
addition, the 10-nm NPs has higher transvascular flux into tumor tissue due to their smaller size
suggesting that the 10-nm NPs will have higher accumulation in tumor tissue. We also demonstrated that
10-nm NPs can penetrate into the tumor's interstitial space quite well. Therefore, a single-stage
nanoparticle delivery system that is ~10 nm, PEGylated, and releases drug once it reaches the tumor may
already perform better than a 1 00-nm particle in both tumor accumulation and penetration (assuming they
have the same half-life). Further work is necessary to investigate the biodistribution of the 10-nm and
100-nm NPs (along with other sizes) to obtain the optimal size for passive tumor targeting and reduced
accumulation in normal tissue. If 10-nm NPs performs similar to 100-nm NPs in these two respects, then
single-stage 10-nm NPs (or NPs > ~5 nm and < -15 nm) may provide a good trade-off between
preferential accumulation in tumor and high interstitial transport. In this case, a multistage system can
also be designed with 10-nm NPs as the first stage carrier that perhaps releases 3-nm drug nanocarriers. In
addition to size-change, a multistage system allows a multi-encapsulation strategy so that the drug is
released only after multiple trigger mechanisms.
In addition to the size, the NPs' material and surface properties must also be considered. The very
long half-life of 100-nm PEGylated liposomes is not only due to the 100-nm size but also because of the
nature of PEGylated liposomes. Doxil® has a low clearance (mean: 0.03 liter/h/m2) and long half-life
(mean: 36.4 h, some have reported times of 40-60 hours), typical of drugs encapsulated in PEGylated
liposomes. However, we have observed that PEGylated -100nm SilicaQD NPs only have a half-life of
12.9 ± 2.4 hrs. Even though both Doxil@ and SilicaQD NP are approximately the same size and
PEGylated, there are still differences in the surface moiety and perhaps compressibility that play a major
role in the particles' pharmacokinetics. So one cannot realistically consider the design of a nanoparticle
drug delivery system based on size alone but also take into account the material used for the core and the
surface properties. The surface PEGylation is difficult to emulate on NPs of different materials. Since
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most types of NPs can only be synthesized within a certain size range, compromises sometimes need to be
made between the size, core material, and surface that are used to obtain the desired properties. In the
case of a drug delivery particle, compromises need to be made regarding the many properties desirable in
a drug nanocarrier (see section 1.4). A major obstacle with multistage drug delivery systems is that they
must exhibit the desirable properties of drug delivery nanoparticles (high entrapment efficiency may be
difficult) in addition to changing size.
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Chapter 4
Electrically Controlled Catalytic Growth of
Nanowires
4.1 Introduction
One dimensional nanostructures such as nanorods, carbon nanotubes and nanowires are
promising candidate materials for bottom-up assembly of electronic and optoelectronic devices. 1 -D
nanomaterials have demonstrated excellent electrical properties that rival conventionally-made materials,
creating the possibility that they could function as building blocks for self-assembling nanoelectronic
devices and circuits without having to resort to complex and costly semiconductor microfabrication
facilities. Several groups have used these nanomaterials to demonstrate miniature sensors, light emitting
diodes (LED), lasers, diodes, transistors (1), bioanalytical devices (2), etc. However, to realize bottom-up
assembly of complex nanocircuitry based on 1 -D nanocomponents, strategies have to be developed
having the ability to organize large numbers of components in a massively parallel manner into
predetermined functional architectures and electrically addressable nanoscale devices. While fluidic and
electric field self-assembly methods can direct nanowires into limited scale structures such as ordered
arrays, these techniques are not appropriate for maneuvering them in large numbers into an integrated
nanowire circuit.
117
Several approaches have been developed to place a nanowire in between two electrodes. In this
way, its electrical characteristics can be directly probed and used in a device. To place a nanowire in
between two electrodes, the location and orientation need to be controlled. Aligning nanowires and
nanorods with patterned electrodes could potentially be an inefficient and time-consuming process. DC
and AC electric fields have been shown to align the growth direction of carbon nanotubes (3) and
nanowires (4). Another method involves directing nanowires (5) and nanorods (6) in between electrodes
using an electric-field based alignment method. When a voltage is applied between two micropatterned
electrodes, charge carriers of opposite sign are accumulated at opposite electrodes and an electric field is
produced. If a nanowire in solution approaches this field, the applied electric field induces a polarization
within the wire and attracts the wire toward the electrode. The attraction results in the wire bridging the
gap between the electrodes, which quenches the attraction and prevents a second wire from bridging the
gap. In addition, magnetic fields have been shown to manipulate dielectric nanowires suspended in liquid
media (7).
A microfluidic approach has also been used to direct the assembly of nanowires into functional
arrays (8). Microfluidic channels are aligned under a microscope with electrodes which have been
previously patterned on a substrate. A drop of nanowire suspension is flowed into the microchannels by
capillary forces, and solvent evaporation aligns the nanowire at the edge of the channel.
The Langmuir-Blodgett (LB) transfer technique can be used to produce large two dimensional
arrays of packed nanowires (9) and nanorods (10). This technique has been shown to transfer 1 -D
structures such as hydrophobized silver nanowires, which are found to float at a water-air interface.
Compression of the interface increases the surface density of nanowires, and aligns them into ordered
phases and controlling the pitch between the wires. This monolayer can be transferred onto a substrate by
slowly withdrawing the substrate through the interface and by keeping the surface pressure constant.
Multiple steps of LB assembly and deposition, followed by photolithography, have also resulted in
hierarchical crossbar arrays (1]).
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We have developed a method of combining the synthesis and assembly of nanowires in a
predetermined architecture in a single step (12). Our novel method first defines the position of nanowire
growth by depositing catalytic particles on lithographically defined positions on a substrate and then
induces nanowire to growth from the catalytic particle using an applied electric field. The macroscopic
flow of nanowire material is also guided by the applied electric field. Since the nanowires are grown to
bridge the gap between electrodes, each nanowire device is already electrically addressable. Our
technique can fabricate many nanowire devices in parallel and is thus highly scalable.
Semiconducting nanowires are commonly synthesized using the vapor-liquid-solid phase (VLS)
technique (13). Precursor material from laser ablation of source material or feed gas delivers the source
materials for nanowire growth. The source material is flowed and exposed to a heated catalyst particle.
The source enters the catalyst and saturates the particle. When supersaturation of the catalyst is reached,
the source element phase separates (solidies) and grows outward out from the catalyst particle, forming a
"nanowire". A solution phase analog of the VLS mechanism is the solution-liquid-solid (SLS) growth
(14). In SLS, the catalyst particle and source material are in solution. The SLS technique limits the
catalyst particles to those that are active below the boiling temperature of the solvent. The Park group has
demonstrated SLS nanowire growth from bismuth catalysts deposited on a substrate (15). We extend
upon this technique by using voltage and electric field to influence the growth of the nanowires.
4.2 Materials and Methods
Note: The experiments were performed in collaboration with Dr. August Dorn.
4.2.1 Materials
Cadmium oxide (99.999%, Alfa Aesar), 1 -tetradecylphosphonic acid (TDPA, 98%,), and selenium shot
(99.999%) were purchased from Alfa Aesar. Trioctylphosphine oxide ( 99%) was purchased from Sigma-
Aldrich. Tri-n-butylphosphine (99%) was purchased from Strem Chemicals.
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4.2.2 Experimental Setup
Schematic and images of the experimental setup are shown in Figure 4.1 and 4.2. The tube and
clips used for mounting the sample were made of stainless steel and the wires were insulated with Teflon
(Figure 4.2). Quartz or degenerately doped silicon with a 300nm oxide layer were used as sample
substrates and electrodes were defined with optical lithography and typically consisted of a 5nm Ti
adhesion layer, a 50 nm platinum layer, and a 20 nm bismuth layer.
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Figure 4.1. Schematic of the experimental setup. The actual flask has a fourth neck for inserting a
temperature sensor which is not shown.
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Figure 4.2. Images of the experimental setup used to apply bias voltages to the electrodes in the precursor
solution
Figure 4.3. SEM images of 20 nm Bi layers thermally
being exposed to wire synthesis conditions.
evaporated onto Pt electrodes a) before and b) after
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4.2.3 Nanowire Synthesis
CdSe nanowire synthesis was performed using a modified version of (15). For the cadmium
precursor, cadmium oxide (19.2 mg), trioctylphosphine oxide (20 g), and 1 -tetradecylphosphonic acid
(85.6 mg) were loaded into a four-neck flask and heated to 140'C for 30 min under vacuum. The solution
was then placed under 1 atm of nitrogen and heated to 300'C over the course of 1 hour. The solution
turned clear upon formation of the cadmium-TDPA complex. For the selenium precursor, selenium shot
was dissolved in tri-n-butylphosphine overnight in a glove box under nitrogen atmosphere, to form TBP-
selenium (25 wt %), a clear colorless liquid. After the cadmium-TDPA complex was formed, the
temperature was reduced to 285'C, the sample was lowered into the cadmium-precursor solution, the
voltage was applied using a Yokogawa DC voltage source, and 80 pL of the selenium precursor were
injected. After a period of typically 300 s, the sample was withdrawn from the solution and the voltage
was set back to 0 V. Once the flask had cooled to below 150'C, the sample was removed and rinsed with
hexanes.
4.3 Results and Discussion
The center of the experimental setup consisted of a substrate patterned with pairs of optical
lithography defined platinum electrodes separated by a gap (Figure 4.1). The surface of the electrodes was
covered with bismuth catalysts islands, which formed spontaneously when layers of bismuth were
thermally deposited onto the platinum layer (Figure 4.3) (16). The substrate was attached to a custom-
built pole that allowed electrical contact with the platinum electrodes (Figure 4.2) and submersion into a
round bottom flask containing a solution of Cd precursors (cadmium-TDPA complex) at 285 'C. A
voltage was applied (varied from 0 to 5 V) between the platinum electrodes and a selenium precursor
(TBP-Se) was injected. CdSe nanowires were allowed to grow for 5 minutes before the substrate was
withdrawn from solution and rinsed with hexane.
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Figure 4.4. Voltage and electric-field dependence of CdSe-nanowire growth. (a-d) CdSe-wire growth off
5 nm Ti/50 nm Pt/20 nm Bi electrodes on quartz substrates at a series of voltages from 0 V to 5 V at
285'C for 300 s. (e) Finite element simulation of the magnitude of the electric field in the substrate plane
(f) Scanning electron microscope image of the CdSe wire mat from (d)
Optical and scanning electron microscopy revealed that the nanowire growth was highly
dependent on the applied electric potential and wire growth did not occur without an applied electric
potential (Figure 4.4, 4.5a). This observation differs from previous reports that demonstrated nanowire
growth in solution or on substrates without the need of an applied electric potential (17-19). This
surprising result suggests electrically controlled catalytic nanowire growth can be used to selectively
induce nanowire growth in predetermined locations only by applying a modest electric potential. Another
surprising observation was that the nanowires only grew from the negative electrode. SEM images also
revealed that the individual wires were randomly oriented. However, the macroscopic flow of nanowire
material appeared to be guided by the applied electric field. We also tested the effect of applying an
electric field perpendicular to the plane of the electrodes using a conducting back gate (Figure 4.9), but
this did not have any noticeable effects on the nanowire growth.
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Figure 4.5. Morphology and crystal structure of CdSe nanowires grown by electrical excitation (a)
Scanning electron microscope image of microstructured 5 nm Ti/50 nm Pt/20 nm Bi electrodes on a
degenerately doped, conducting silicon substrate with a 300 nm layer of insulating thermal oxide after
wire growth at 0.5 V at 285*C. Wire growth emanates from the grounded electrodes in the region of
highest electric field in the gap, while two identical electrodes to the right, that are not biased, show no
wire growth. (b) Close up of a). (c) Electron-diffraction pattern from a single wire recorded with a TEM
in nanobeam mode, showing the typical wurtzite <001> growth direction. (d) High-resolution TEM image
of a nanowire with stacking faults (20).
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Figure 4.6. High-resolution TEM images of CdSe wires. (a) Tip of a wire (b) Example of a Y-branched
wire. (c) example of a single crystalline segment. (d) wire segment with a high degree of twinning and
phase changes along the axial growth direction.
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We characterized the CdSe using high resolution transmission electron micrograph (HRTEM)
and electron diffraction. The results indicated that the crystal structure of the wires were mainly wurtzite
(Figure 4.6c) and the nanowires grew along the <001> direction (Figure 4.5c). Similar to previous reports
of SLS growth of nanowires, HRTEM of the nanowires showed stacking faults, segments with zinc
blende orientation (Figure 4.6d), and Y-branched structures (Figure 4.6b) (21). Scanning transmission
electron microscopy of the nanowires with energy-dispersive X-ray (EDX) elemental analysis showed a
1:1 ratio composition of Cd to Se along the length of the wire (Figure 4.7), confirming that the nanowires
were composed of CdSe. The diameter of the nanowire was found to correlate with the size of the
bismuth island that it grew from, which can be controlled through varying the thickness of the bismuth
film deposited (Figure 4.8). The average diameter of the wire was about 30% smaller than the diameter of
the bismuth catalyst.
During the wire-growth process, the conductivity measured across the electrode was typically
between 10 kQ and 10 MO. The conductivity remained the same or increased slightly after injection of
the selenium precursor, possibly due to bridging of the gap between the electrodes by the nanowires.
Moreover, the conductivity remained the same even as the selenium precursors became depleted from
solution. The wire growth appeared to be dependent primarily on the applied voltage and not on the total
charge that passed through the electrodes (as in electrodeposition).
We used Maxwell® Ansoft simulation software for finite-element modeling of the electric field
in the substrate plane (Figure 4.4f). The TOPO precursor solution was modeled as an insulator with a
dielectric constant of 2.5. The regions of wire growth from imaging were found to have a strong
association with the locations in the simulation with high electric field strengths and the corresponding
high surface charge density induced in the electrodes. The electrode asymmetry of nanowire growth in
our experimental result compared to simulation was due to the nanowires only growing from the negative
electrodes. The simulation showed the maximum electric field amplitude was located at the edge of the
electrode due to electric field bunching (22), which was also the region of the highest nanowire growth.
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Figure 4.7. Elemental analysis of a wire with Scanning Transmission Electron Microscope (STEM). The
red trace indicates the selenium concentration and the green trace indicates the cadmium concentration
along the highlighted wire segment. The table lists the average percentage of selenium, cadmium, and
bismuth atoms along the marked wire segment based on the integrated number of counts.
Figure 4.8. CdSe wires grown off bismuth layers with different thicknesses. Scanning electron
microscope images of CdSe nanowires grown off Pt electrodes at 285 'C at a bias of 2 V for 300 seconds
with (a) a 20 nm Bi layer and (b) a 2 nm layer.
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We next characterized the fluorescent properties of the wire mat. The photoluminescence
spectrum peaked at 713 nm, which corresponded to the bulk CdSe bandgap of 1.74 eV. Since the
diameter of the wire (~20 ± 10 nm) was notably bigger than the Bohr diameter of bulk CdSe (11.2 nm),
quantum confinement effects were negligible.
We next performed photoconductivity measurements to demonstrate that electrically controlled
nanowire growth can be a potential method for fabricating devices such as a photodetectors. An Ar-ion
laser (514 nm line) was used to illuminate the nanowire mat in between a 10 im wide gap between the
electrodes after nanowire growth and the I-V curve was measured (Figure 4.11). Over 80% of the devices
showed photoconductivity without any additional post-treatment beyond hexane rinsing. The I-V curve
showed high symmetry when voltage was applied in either direction, indicating the nature of the contacts
on both electrodes was similar. The resistance of the wire mat in the dark was above 1 TQ and the
resistance near saturation (3 x 105 W m-2 illumination) was ~20 MQ, indicating an on/off ratio of ~10 5.
The near-random orientation of the nanowire showed no polarization dependence in photoconductivity,
similar to another predominantly random nanowire network from a previous report (23).
We attempted to create an electrically addressable single nanowire device by inducing the growth
and alignment of a single nanowire to bridge the gap in between the electrodes. A single large bismuth
particle was placed near the tip of each platinum electrode and an electric field was placed across the
electrode as before. Several CdSe nanowires grew off the bismuth bead from the negative electrode;
however, the applied electric field did not have an observable effect on the orientation of the nanowire
and thus the wires did not preferentially bridge the gap (Figure 4.10). Perhaps the kinetics of the wire
growth process was too fast or the temperature was too high for the forces from the applied electric field
to have a significant effect. This problem may be a major limitation in applying this method for bottom-
up assembly of nanocircuitry.
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We proposed a possible mechanism for the strong dependence of nanowire growth on applied
electric field. The large difference in work function between bismuth and platinum may result in
extraction of electrons from the bismuth islands into the platinum substrate. The resulting lower work
function of the bismuth (slight positive charge) and lower electron density may result in quenching of its
catalytic activity, and in turn the inability to catalyze nanowire growth at zero bias. The lower electron
density may hinder the ability for the catalytic particle to undergo redox reactions with the Cd 2+ and Se2-
precursors. This proposed mechanism also explains the growth of wires only from the negative electrode
as the applied negative voltage can offset the lower work function and compensate for the lower electron
density. However, further modeling and characterization is necessary to investigate and validate the
microscopic mechanism behind electrically controlled nanowire growth.
We demonstrated that growth of CdSe nanowires through the SLS mechanism under certain
conditions can be strongly influenced by an applied electric field. This method adds to the arsenal of tools
scientists can use to integrate nanocomponents for large scale integration. In addition to growth of CdSe
nanowires, further works have demonstrated this technique can be applied to growth of InP nanowires (24)
and conversion of CdSe nanowires into Ag2Se nanowires (25). The low temperature necessary for the
growth of nanowires via the SLS mechanism compared to VLS makes this a promising approach for
incorporation with conventional silicon-based technology.
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Figure 4.9. CdSe wires grown on a substrate with a conducting back gate. (a) CdSe wires grown at 285*C
at a bias of 2V for 300 seconds on a doped silicon substrate with 300 nm of thermal oxide. The electrode
geometry is the same as the one used in Figure 4.4. (b) Close up of the region highlighted in (a).
Figure 4.10. CdSe wires grown off single bismuth beads. (a) Two single Bi beads defined by electron
beam lithography with a diameter of about 80 nm and a thickness of 50 nm on two platinum electrodes.
(b) Sample similar to the one shown in (a) after CdSe wire growth at 275'C at a bias of +0.5V for 300s.
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Figure 4.11. Photoconductivity. Current-voltage characteristic of a sample grown at 0.5 V, as shown in
Figure 4.5b, under illumination with the 514 nm line of an Ar-ion laser at 3 x 105 W m-, Inset:
corresponding photoluminescence spectrum.
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